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When I heard the learn’d astronomer, 
When the proofs, the figures, were ranged in columns before me, 
When I was shown the charts and diagrams, to add, divide, 
and measure them, 
When I sitting heard the astronomer where he lectured with 
much applause in the lecture-room, 
How soon unaccountable I became tired and sick, 
Till rising and gliding out I wander’d off by myself, 
In the mystical moist night-air, and from time to time, 
Look’d up in perfect silence at the stars. 
 
—Walt Whitman 
Leaves of Grass 
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Abstract 
ASH1L (absent, small, or homeotic-like 1) is a histone lysine methyltransferase 
(KMTase) that is overexpressed in cancer and activates oncogenic HOX genes. Small molecule 
inhibitors of ASH1L would be invaluable tools to investigate the role of ASH1L in cancer; 
however, no ASH1L inhibitors have been reported to date. Previous studies of ASH1L’s 
catalytic SET domain identified an autoinhibitory loop that blocks access of histone substrate to 
the enzyme active site. We used nuclear magnetic resonance (NMR) and X-ray crystallography 
to identify conformational heterogeneity in the ASH1L autoinhibitory loop and nearby SET-I 
loop, two structural features that regulate the enzymatic activity of the SET domain. These 
studies suggested that conformational heterogeneity in the autoinhibitory loop region of the 
ASH1L SET domain may create transient pockets into which small molecule ligands could bind.  
We took a fragment-based drug discovery (FBDD) approach to probe the ASH1L SET 
domain for potential small molecule binding sites and then construct new ligands specific to 
ASH1L. FBDD identified a ligand that binds to the ASH1L autoinhibitory loop region. We used 
information from NMR and crystallographic studies to optimize the fragment-like ligand into a 
first-in-class potent and specific ASH1L inhibitor. Structural studies indicate that ASH1L 
inhibitors block enzymatic activity by stabilizing the autoinhibited conformation of the SET 
domain. Our current most potent compounds inhibit ASH1L activity with IC50 of ~4 μM and 
bind to ASH1L with ~1 μM affinity, representing greater than 1000-fold improvement over the 
fragment screening hit. Our work identified the first ASH1L inhibitor and represents the first 
example of successfully applying FBDD to KMTases. 
xi 
 
Using our ASH1L inhibitors, we took a combined genetic and pharmacologic approach to 
investigate the role of ASH1L in leukemia and breast cancer. We found that ASH1L is required 
for proliferation of breast cancer and leukemia cells, and that ASH1L activates HOXA genes and 
MEIS1 in leukemia. Moreover, inhibition of the ASH1L SET domain downregulated HOX gene 
expression and induced differentiation of leukemia cells transformed by MLL-AF9. Our results 
demonstrate cellular efficacy of ASH1L inhibitors and uncover a new role for the ASH1L SET 
domain in acute leukemia.
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Chapter 1. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for 
inhibitor development

 
 
Abstract 
Methylation at histone 3, lysine 36 (H3K36) is a conserved epigenetic mark regulating 
gene transcription, alternative splicing, and DNA repair. Genes encoding H3K36 
methyltransferases (KMTases) are commonly overexpressed, mutated, or involved in 
chromosomal translocations in cancer. Molecular biology studies have demonstrated that H3K36 
KMTases regulate oncogenic transcriptional programs. Structural studies of the catalytic SET 
domain of H3K36 KMTases have revealed intriguing opportunities for design of small molecule 
inhibitors. Nevertheless, potent inhibitors for most H3K36 KMTases have not yet been 
developed, underlining the challenges associated with this target class. As we now have strong 
evidence linking H3K36 KMTases to cancer, drug development efforts are predicted to yield 
novel inhibitors in the near future. 
                                                          
Rogawski DS, Grembecka J, and Cierpicki T. H3K36 methyltransferases as cancer drug targets: 
rationale and perspectives for inhibitor development. Future Med Chem. Under review. 
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Introduction 
Cellular development and differentiation are controlled by post-translational 
modifications on DNA and histone proteins, forming an epigenetic (“above the genes”) 
regulatory network. One major class of epigenetic modifications is histone lysine methylation, 
which alters the chromatin environment and enhances or suppresses binding of regulatory 
cofactors [1,2]. Methyl marks are installed by histone lysine methyltransferases (KMTases), 
removed by demethylases, and bound by a variety of methyl-reader proteins that initiate 
downstream effects. Methylation occurs at multiple different lysine residues on histone proteins, 
the most extensively studied of which include histone 3 lysine 4 (H3K4), H3K9, H3K27, 
H3K36, H3K79, and H4K20, with methylation at different sites signaling the recruitment of 
different cofactors [1,3]. The degree of methylation (mono-, di-, or trimethylation) at a particular 
site is an additional variable that affects cofactor recruitment. For example, H3K4 trimethylation 
is associated with the transcription start sites of active genes, where one of its multiple functions 
is to recruit the transcription factor TFIID complex, an essential component of the RNA 
polymerase II pre-initiation complex [4]. In contrast, H3K27 trimethylation is found in regions 
of repressed chromatin, where it plays a role in promoting chromatin compaction [5].  
The human genome encodes approximately 50 KMTase proteins. With the exception of 
DOT1L, these KMTases contain a catalytic Suppressor of variegation 3–9 [Su(var)3–9], 
Enhancer of zeste [E(z)], and Trithorax (Trx) (SET) domain responsible for KMTase activity [2]. 
The core SET domain is approximately 130 amino acids in length and catalyzes transfer of a 
methyl group from S-adenosyl methionine (SAM) to the ε-amino group of a histone lysine. 
Interestingly, an increasing number of SET domain-containing proteins have been found to also 
methylate non-histone proteins [2]. Most SET domain-containing proteins contain additional 
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domains that recruit the SET domain to its target or have SET domain-independent functions 
[6,7]. Furthermore, some SET domain-containing proteins function in protein complexes that 
regulate their catalytic activity [2].  
In cancer, epigenetic pathways are commonly disrupted, causing aberrations in gene 
expression and genome integrity (reviewed in [8]). In particular, KMTases play major roles in 
driving proliferation and halting differentiation by modifying transcription and other DNA-
templated processes [9–11]. Over the past decade, KMTases have emerged as important drug 
targets for both industrial and academic research groups. Some progress has been made, most 
notably by selective inhibitors for the EZH2 and DOT1L KMTases that have reached clinical 
trials for the treatment of non-Hodgkin lymphoma and acute leukemia, respectively [12,13]. The 
KMTase inhibitor field, however, has yet to experience the widespread success of kinase 
inhibitors [14], despite similarities in the reactions catalyzed by these two classes of enzymes. 
Indeed, selective inhibitors for many KMTases remain unavailable. 
Methylation at H3K36 represents a particularly important chromatin mark implicated in 
diverse forms of cancer. KMTases with specificity toward H3K36 are overexpressed in cancer 
cells and have been characterized as regulators of cell growth, differentiation, stemness, and 
DNA repair pathways [15–17]. However, very few selective and cell-active small molecule 
inhibitors of H3K36-specfic KMTases have been reported to date. In this chapter, we provide an 
overview of cellular pathways involving H3K36 methylation and discuss the diverse functions 
carried out by the eight different human H3K36-specific KMTases. Then we analyze structural 
characteristics of the catalytic SET domain of H3K36 KMTases and evaluate prospects for their 
inhibition by small molecules. We conclude with a discussion of the challenges and opportunities 
for targeting these proteins. 
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H3K36 methylation regulates diverse processes implicated in cancer 
 
 H3K36 methylation participates in a wide variety of nuclear pathways. Many of these 
processes, including transcriptional regulation, alternative splicing, and DNA repair, are 
dysregulated in cancer.  
Transcriptional regulation  
On a genome scale, H3K36 methylation is enriched within the transcribed region of 
active genes rather than regulatory sites [18,19], with the highest levels at the 3’ end of genes 
[20]. H3K36 methylation plays a key role within gene bodies by preventing cryptic intragenic 
transcription, which may generate toxic proteins or waste cell resources [21]. In this way, H3K36 
methylation is associated with active genes but actually has a repressive effect on chromatin 
structure within these genes. In yeast, the sole H3K36 methyltransferase is Set2, which is 
recruited to actively transcribed genes by binding to the hyperphosphorylated C-Terminal 
Domain of RNA Polymerase II (Pol II) [22]. Methylation of H3K36 by Set2 recruits the Rpd3S 
histone deacetylase (Figure 1.1A), which produces chromatin compaction and prevents aberrant 
transcription from cryptic intragenic promoters in the wake of Pol II [23]. H3K36 methylation 
further suppresses cryptic transcription by preventing the incorporation of new, acetylated 
histones over open reading frames (ORFs). This role depends on methylated H3K36 recruiting 
chromatin remodelers Isw1b and Chd1and preventing H3 binding to the histone chaperone Asf1 
[24,25].  
H3K36 methylation similarly prevents cryptic intragenic transcription in mammals. The 
human H3K36 tri-methyltransferase and Set2 homolog SETD2 is required for preventing 
intragenic transcription initiation in 11% of genes [26]. This function does not depend on histone 
deacetylases as in yeast, but on recruitment of histone demethylases and chaperones. In 
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embryonic stem cells, the H3K36me3 reader protein MRG15 recruits the JARID1B histone 
demethylase to intragenic regions, where it removes H3K4me3 to prevent cryptic intragenic 
transcription and facilitate transcriptional elongation of functional full-length mRNAs [27] 
(Figure 1.1A). Interestingly, human LSD2, a second H3K4 demethylase that maintains a 
repressive chromatin environment in gene bodies to facilitate optimal transcriptional elongation, 
forms a complex with the H3K36 KMTase NSD3 [28]. Additionally, H3K36me3-modified 
chromatin recruits the FAcilitates Chromatin Transcription (FACT) histone chaperone complex, 
which helps restore chromatin structure following transcriptional elongation [26]. 
Alternative splicing 
Splicing pathways are deregulated in cancer, resulting in expression of gene isoforms that 
contribute to oncogenic processes [29]. H3K36me3-modified nucleosomes are enriched within 
exons [30], and accumulating evidence indicates that H3K36 methylation signals to the splicing 
machinery. As an example, the human fibroblast growth factor receptor 2 (FGFR2) gene 
undergoes tissue-specific alternative splicing that is controlled by pyrimidine tract binding 
protein (PTB). Knockdown or overexpression of the H3K36 tri-methyltransferase SETD2 causes 
inclusion or exclusion, respectively, of the PTB-regulated exon in FGFR2. Further experiments 
showed that PTB is specifically recruited to exons labeled with H3K36me3 by interacting with 
MRG15, an H3K36 methyl-reader protein that is present in multiple protein complexes [31] 
(Figure 1.1B). In addition to the H3K36me3/MRG15/PTB alternative splicing pathway, multiple 
PWWP domain-containing proteins that recognize H3K36me3 have been implicated in 
alternative splicing [32,33]. For example, the PWWP domain-containing protein ZMYND11 
localizes primarily to gene bodies due to specific recognition of K36me3 on histone variant 
H3.3. ZMYND11 promotes intron retention at hundreds of sites by interacting with and 
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antagonizing the function of the splicing regulator EFTUD2 [33]. On the other hand, alternative 
splicing has been shown to regulate H3K36 methylation. Deletion of splicing sites or 
pharmacological inhibition of splicing leads to redistribution of H3K36 tri-methylation, reduces 
overall levels of H3K36 tri-methylation, and blocks SETD2 recruitment to chromatin [34,35]. 
These findings suggest regulatory cross-talk between H3K36 methylation and alternative 
splicing pathways. 
DNA repair 
Genome instability is a key characteristic of cancer, and H3K36 methylation has a 
conserved role in DNA repair. In yeast, H3K36 methylation mediated by Set2 promotes the Non-
Homologous End Joining (NHEJ) pathway of DNA repair during the G1 phase of the cell cycle, 
whereas H3K36 acetylation mediated by Gcn5 promotes Homologous Recombination (HR) 
repair during the S and G2 phases [36,37]. The mammalian Set2 homolog SETD2 also regulates 
DNA repair, but in the opposite direction from Set2, as SETD2 promotes HR rather than NHEJ. 
Histones tri-methylated at H3K36 by SET2D provide a constitutive binding site for the LEDGF 
PWWP domain. Once a DNA double-strand break occurs, LEDGF recruits CtIP, which performs 
5’ end resection to produce a single stranded 3’ overhang (Figure 1.1C). Recruitment of major 
HR repair factors downstream of CtIP, such as RPA and RAD51, also depends on SETD2-
mediated H3K36 tri-methylation [38]. In cells with depleted SETD2, double-strand break repair 
proceeds via the error-prone microhomology-mediated end-joining pathway, leading to deletions 
between sequences of microhomology [38]. SETD2 is also responsible for regulating DNA 
mismatch repair through its interaction with MutSα [39]. These studies provide mechanistic basis 
for the genome instability observed in SETD2-deficient cancers (see below).  
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Another H3K36 KMTase involved in DNA repair is SETMAR, a gene that evolved from 
fusion of a SET domain to a transposase domain. Upon radiation damage, H3K36me2 levels are 
increased in a SETMAR-dependent manner. Depleting SETMAR or expression of H3 with 
mutated K36 decreases Ku70 and NBS1 recruitment, thereby decreasing efficiency of the NHEJ 
repair pathway [40] (Figure1.1C). The SET domain of SETMAR is also required for the DNA 
damage response at stalled replication forks and efficient restarting of stalled replication forks 
[41]. Interestingly, SETMAR does not methylate recombinant nucleosomes in vitro [42], 
suggesting that SETMAR may indirectly produce H3K36me2 after DNA damage. 
The reciprocal relationship between H3K36 and H3K27 methylation 
How different epigenetic marks interact with each other to produce signaling outputs has 
important implications for epigenetic inhibitor development. H3K36 methylation interacts in an 
antagonistic fashion with H3K27 tri-methylation, a repressive mark mediated by Polycomb 
Repressive Complex 2 (PRC2). For example, in Drosophila the H3K36-specific KMTase Ash1 
activates Hox genes during development by functioning as an anti-repressor and antagonizing 
repressive H3K27 methylation installed by PRC2 [43]. In human HeLa cells, H3K36 
methylation and H3K27 methylation are rarely found together on histone H3. In fact, H3K36 
pre-methylation inhibits PRC2 H3K27-KMTase activity in in vitro assays [44]. Conversely, 
H3K36 KMTases are inhibited by ubiquitinated H2A, a mark made by Polycomb Repressive 
Complex 1 [45]. As development proceeds, however, the PRC2 complex must invade active, 
H3K36-methylated chromatin to silence certain genes. In this case, PRC2 targeting and 
spreading is mediated by Polycomb-like proteins with Tudor domains that specifically recognize 
H3K36me3 [46]. Disruption of the balance between the H3K36 and H3K27 methylation pattern 
is observed in multiple cancers (discussed below) (Figure 1.1D). In particular, cancers with 
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chromosomal fusions involving H3K36 KMTases have disruptions in H3K27 methylation that 
drive oncogenesis, in addition to aberrant H3K36 methylation [16,47]. 
 
Figure 1.1. The functions of H3K36 methylation in biology. (A) H3K36 methylation plays a 
conserved role in suppressing intragenic transcription. Methylated H3K36 recruits histone 
deacetylases (yeast) or histone demethylases (humans) to maintain a suppressive transcriptional 
environment within gene bodies. (B) Splicing regulators including PTB are recruited to loci by 
H3K36 methylation. (C) Methyl marks installed by the SETMAR and SETD2 KMTases are 
important for recruiting mediators of the DNA damage response including Ku70/Ku80, MRE11-
RAD50-NBS1 (MRN), and CtIP. (D) Methylated H3K36 antagonizes PRC2-mediated H3K27 
methylation and gene silencing. In NSD2 Low cells, active genes are marked by H3K36 
methylation, whereas lower expressed genes are marked by H3K27 methylation. In NSD2 High 
cells (as in t(4;14) multiple myeloma), overexpression of NSD2 increases genome-wide levels of 
H3K36 methylation, forcing accumulation of H3K27 methylation at a subset of silenced loci. 
Adapted from [47]. 
 
H3K36 KMTases play important and varying roles in carcinogenesis 
 
Given the importance of H3K36 methylation in diverse cellular processes, it is not 
surprising that H3K36 KMTases have been implicated both as oncogenes and tumor suppressors 
in cancer. The human genome encodes at least eight H3K36 KMTases (Figure 1.2), each of 
which contains a SET domain responsible for transferring a methyl group from SAM to the 
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substrate lysine. Although these proteins have all been reported to methylate H3K36, they vary 
in the number of methyl groups transferred as well as whether they methylate additional 
substrates. NSD1-3, ASH1L, and SETD2 have closely related catalytic SET domains and show 
H3K36 methylation specificity in vitro and in vivo, while SMYD2, SETMAR, and SETD3 have 
more distantly related SET domains with less well characterized activities toward H3K36 
(Figure 1.2). Of these KMTases, the NSD proteins are perhaps the best characterized 
oncoproteins, as they play important roles in multiple cancer types and are found in fusion 
proteins due to chromosomal translocations in acute myeloid leukemia (AML) and multiple 
myeloma (MM) [10,16]. The ASH1L KMTase is also overexpressed in cancer and regulates 
stem cell potential [15]. SMYD2 has oncogenic activity in multiple cancers [48–52], but whether 
this function depends on KMTase activity toward H3K36 or another of its many substrates is 
uncertain.  
 
Figure 1.2. Domain organization of human H3K36 KMTases. SET domain is shown in red. 
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NSD1: Activator of HOX genes in leukemia 
 
NSD1 is a mono- and di- H3K36 KMTase with functions in development and cancer. 
Mutations in NSD1 cause Sotos syndrome, a condition of childhood overgrowth and intellectual 
disability, with a 2.4% increased risk of childhood malignancy [53,54]. A chromosomal 
translocation resulting in the NUP98-NSD1 fusion protein is found in 16% of cytogenetically 
normal pediatric AML and in a smaller portion of adult AML [55]. More than 90% of NUP98-
NSD1-positive leukemias are also positive for internal tandem duplication mutation of the FLT3 
tyrosine kinase (FLT3-ITD), and the two genetic lesions exhibit potent cooperativity resulting in 
a 3-year survival rate of 31% [56]. NUP98-NSD1 induces AML in vivo, sustains self-renewal of 
myeloid stem cells in vitro, and enforces expression of the HOXA7, HOXA9, HOXA10 and 
MEIS1 proto-oncogenes [16]. Expression of the HOXA and MEIS1 oncogenes appears to be 
responsible for the transforming activity of NUP98-NSD1, as inhibition of the DOT1L-AF10 
complex in NUP98-NSD1 leukemia decreases HOXA gene expression and triggers 
differentiation and apoptosis [57].   
NSD1 has also been reported to methylate non-histone proteins, including the p65 
subunit of NF-κB at Lys218 and Lys221. In response to cytokines such as IL-1β and TNFα, 
NSD1-mediated methylation enhances NF-κB’s transcriptional activation and DNA binding 
activities [58], which are active in most cancer cells and regulate genes that control proliferation, 
resistance to apoptosis, angiogenesis, invasion, and metastasis [59]. Conversely, these activating 
marks on NF-κB are removed by the FBXL11 demethylase, and increasing methylation at 
Lys218 and Lys221 by depleting FBXL11 enhances cell proliferation and colony formation of 
colon cancer cells [58]. In addition, mutation of Lys218 and Lys221 on NF-κB showed that 
lysine methylation is required for activating the majority of NF-κB target genes in mouse 
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embryonic fibroblasts (MEFs), including cancer-relevant genes like insulin-like growth factor 1 
(IGF1) and engulfment and cell motility 1 (ELMO1) [58].  
In other contexts, however, NSD1 has been reported to function as a tumor suppressor. In 
bladder cancer cells, for example, inhibition of NF-κB by small molecule causes NSD1-
dependent activation of pro-apoptotic BIM and the cell cycle regulator p21 [60]. Although it is 
not known if NSD1 KMTase activity is involved here, NF-κB inhibition does increase global 
levels of H3K36 tri-methylation in addition to NSD1 expression [60]. Moreover, NSD1 
frequently undergoes inactivating mutations causing premature termination of the protein in head 
and neck squamous cell carcinoma [61], and NSD1 is epigenetically silenced in neuroblastoma 
and glioma [62]. Finally, missense mutations in NSD1 are found in acute myeloid leukemia 
outside of the context of the NUP98-NSD1 fusion [63]. Although the functional consequences of 
these mutations are not known, these observations suggest variable roles for NSD1 in different 
cancer types.  
NSD2 (MMSET/WHSC1): An oncogenic driver in multiple myeloma 
 
NSD2 (also known as MMSET and WHSC1) is an important developmental regulator 
and oncogene. Germline deletion of NSD2 causes Wolf-Hirschhorn syndrome, a developmental 
disorder characterized by craniofacial defects, growth retardation, and microcephaly [64]. NSD2 
has in vivo mono- and di- methyltransferase activity toward H3K36 [10]. Interestingly, NSD2 
has also been reported to dimethylate H4K20, which was proposed to signal the recruitment of 
the DNA damage response regulator 53BP1 to sites of DNA damage [17,65], but other groups 
have not found evidence supporting this model [66,67].  
NSD2 is a potentially attractive target for drug development due to its well characterized 
role in multiple myeloma (MM). In 15% of MM, the t(4;14)(p16.3;q32.3) translocation places 
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the NSD2 gene under control of the immunoglobulin heavy-chain promoter/enhancer, leading to 
overexpression of NSD2, which is believed to be the key transforming factor [68]. In human 
myeloma cells harboring the t(4;14) translocation, overexpressed NSD2 leads to aberrant 
patterns of H3K36 methylation, causing a shift away from normal plasma cell gene expression 
programs and increased expression of cancer-associated genes [10]. Expression of NSD2 is 
sufficient to rescue tumor growth of myeloma cells in which the t(4:14) translocation has been 
inactivated [10], and knockdown of NSD2 in a t(4;14) mouse xenograft model causes dramatic 
reduction in tumor growth [47]. Importantly, the KMTase activity of the NSD2 SET domain is 
required for the epigenetic changes and oncogenic effects caused by NSD2 overexpression 
[10,47].  
Beyond multiple myeloma, expression of NSD2 is sufficient to transform MEF cells 
lacking the p19
ARF
 tumor suppressor, suggestive of it having a role as a general oncoprotein [10]. 
Indeed, NSD2 is overexpressed in neuroblastoma, lung, colon, and bladder cancer [69,70], and is 
required for proliferation of neuroblastoma cells and brain-derived neural stem cells [70]. An 
E1099K mutation in the SET domain of NSD2 was identified in a range of human cancer cell 
lines and tumor samples, including ALL, chronic lymphocytic leukemia (CLL), lung cancer, and 
stomach cancer [71,72]. The mutation appears to result in a hyperactive enzyme, as H3K36me2 
levels are increased in cell lines harboring E1099K NSD2 [71,72]. Thus, the t(4;14) translocation 
in MM and the E1099K mutation in other cancers both result in increased H3K36me2 levels that 
drive oncogenesis. 
NSD2’s oncogenic role may partially reflect an imbalance between H3K36 and H3K27 
methylation pathways. For example, in t(4;14) MM cells, a global loss of H3K27me3 is observed 
concurrently with a global increase in H3K36me2 [47], as one might predict due to the 
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antagonistic relationship between these two marks. However, the excess H3K36me2 forces local 
accumulation of H3K27me3 at a subset of genes, including tumor suppressors. MM cells with 
t(4;14) translocation are sensitive to EZH2 inhibitors, indicating that the accumulation of EZH2 
and H3K27me3 at tumor suppressor loci enhances myeloma cell proliferation [47,73]. 
Interestingly, in other cancers besides MM, EZH2 and NSD2 are co-regulated in an EZH2/NSD2 
oncogenic axis [74]. EZH2 represses expression of a set of microRNAs that repress NSD2, 
leading to EZH2/NSD2 co-regulation. In prostate cancer for example, the EZH2/NSD2 axis 
confers increased cell proliferation, migration, invasion, stem cell-like properties, and tumor 
growth in a mouse xenograft model [74]. Further studies in prostate cancer have shown that 
NSD2 acts as a co-activator with NF-κB and androgen receptor [75,76], and regulates the 
epithelial to mesenchymal transition by dimethylating H3K36 at the TWIST1 locus and 
activating TWIST1 expression [77]. 
NSD3: Frequently overexpressed in diverse tumor types 
 
NSD3, also known as WHSC1L1, is overexpressed in cancer [78] and catalyzes mono- 
and dimethylation at H3K36 in vitro [79]. In cells NSD3 functions as a transcriptional activator, 
but NSD3’s KMTase activity may contribute only partially to its gene-activating role. For 
example, NSD3 regulates neural crest specification and migration and is required for activation 
of neural crest transcription factors Sox10, Snail2, Sox9, and FoxD3, but the only locus at which 
NSD3 is responsible for H3K36 dimethylation is Sox10 [80]. Similar to NSD1, NUP98-NSD3 
fusion proteins have been reported in AML and myelodysplastic syndrome (MDS) [81,82]. 
NSD3 undergoes copy number amplification in 21% of lung squamous cell carcinomas and 15% 
of breast invasive carcinomas, with a high correlation between copy number and mRNA 
expression, suggesting that NSD3 may function as an oncogenic driver [78]. Indeed, RNAi 
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knockdown of NSD3 in non-small cell lung cancer, colorectal cancer, bladder cancer, and breast 
cancer cell lines with NSD3 overexpression causes reduced cell proliferation due to increased 
apoptosis or cell cycle arrest in the various cancer cell lines [78,83,84]. The breast epithelial cell 
line MCF10A is normally highly dependent on growth factors and forms small acinar-like 
structures in 3D Matrigel culture, but these cells can be transformed by expression of NSD3, 
which confers growth factor-independent proliferation, colony-forming ability in soft agar, and 
expanded and disorganized growth in 3D culture [84]. In the transformed cells, NSD3 
overexpression causes activation of IRX3, a homeobox gene family member, and downregulation 
of TGFBI, a putative tumor suppressor [84]. These findings, combined with frequent 
overexpression of NSD3 in breast cancer, make NSD3 an enticing therapeutic target. 
ASH1L: HOX gene activator with emerging role in cancer 
 
Multiple studies have found that ASH1L is an important transcriptional regulator in 
normal development, but the protein’s role in cancer remains unclear. ASH1L is homologous to 
Drosophila Ash1, a trithorax group protein that activates genes involved in development and 
differentiation [85]. In mammals, ASH1L deficiency causes a major reduction in long-term 
hematopoietic stem cells (HSC) in bone marrow, but surprisingly has very modest effects on 
peripheral blood counts due to increased proliferation of progenitors downstream of HSCs [15]. 
ASH1L-deficient HSCs are also unable to reconstitute bone marrow output when transplanted 
into lethally irradiated mice [15]. These findings indicate that ASH1L maintains quiescence and 
self-renewal potential of long-term HSCs, but whether ASH1L regulates the stemness properties 
of leukemic stem cells is unknown.  
ASH1L has been linked to liver fibrosis, facioscapulohumeral muscular dystrophy, and 
cancer through its role in gene activation [86,87]. ASH1L activates HOXA genes and MEIS1 in 
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mouse HSCs [15] and activates HOXB and HOXC genes in human erythroleukemic K562 cells 
[88]. These findings are highly relevant because HOX genes are oncogenic drivers in many 
different blood and solid tumors [89]. For example, overexpression of HOXA9 is highly 
associated with a poor prognosis in AML [90], and HOXA9 and its collaborator MEIS1 are 
required for survival of MLL-rearranged leukemia cells [91,92]. ASH1L’s KMTase activity is 
required for at least some of its gene activating function, as deletion of the ASH1L SET domain 
in differentiating mouse embryonic stem cells leads to loss of expression of 152 genes, including 
members of the Hox and Wnt familes [93].   
ASH1L is overexpressed in a variety of solid tumors, including thyroid and breast cancer 
[94,95]. In thyroid cancer, ASH1L is overexpressed in tumor-specific truncated forms, although 
what parts of the protein are truncated or what processing events produce them has not been 
explored. Expression of the microRNA miR-142-3p suppresses ASH1L protein expression by 
binding to the ASH1L 3’UTR, an effect correlated with inhibition of colony formation and 
slowing of thyroid cancer cell growth [94]. Interestingly, in mouse embryonic stem cells ASH1L 
is regulated by a different microRNA, miR-290, which downregulates ASH1L expression and 
prevents aberrant overexpression of Hoxa, Hoxb, Hoxc, and Hoxd genes [96].  
SETD2: An important tumor suppressor 
 
SETD2 stands out among the human H3K36 KMTases as the sole mediator of H3K36 tri-
methylation [97] and as a tumor-suppressor in most contexts. In human development, germline 
mutations in SETD2 cause an overgrowth condition with features similar to Sotos syndrome 
[98]. Underexpression and mutation of SETD2 are associated with poor prognosis in breast and 
renal cancer, GI stromal tumors, and acute leukemia [99–103]. SETD2 mutations are more 
common in leukemias with MLL-rearrangements (22%) than leukemias without such 
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rearrangements (5%), and SETD2 loss cooperates with MLL fusions like MLL-AF9 and MLL-
NRIP to create a more aggressive leukemia with increased self-renewal of leukemia stem cells 
[104].  
Numerous studies have examined the tumor suppressor function of SETD2 in kidney 
tumors, in which SETD2 is mutated in 3-12% of clear cell renal cell carcinoma (ccRCC) 
[101,105] and a similar proportion of papillary renal cell carcinoma [106]. Multiple different 
loss-of-function mutations in SETD2 occur within spatially distinct regions of a single renal 
tumor, suggesting strong selective pressure for SETD2 inactivation [107]. Furthermore, micro 
RNA-mediated repression of SETD2 expression occurs broadly in ccRCC tumor samples and 
cell lines, causing reductions in SETD2 function where overt mutations may not be present 
[108].The molecular mechanisms underlying SETD2’s suppression of renal cancer reflect the 
physiological functions of H3K36 methylation in transcript processing and genome integrity, as 
outlined above. Briefly, loss of function of SETD2 in ccRCC results in defects in DNA repair, 
nucleosome dynamics, RNA processing, and DNA methylation [109–112].  
Other H3K36 methyltransferases: SMYD2, SETMAR, and SETD3 
 
 As a member of the SMYD family of proteins, SMYD2 contains a bipartite SET domain 
split by a zinc-finger MYND domain. SMYD2 promotes cancer cell proliferation in head and 
neck squamous cell carcinoma and esophageal squamous cell carcinoma [49,50], and 
overexpression of SMYD2 is a poor prognostic factor in pediatric acute lymphoblastic leukemia 
(ALL), gastric cancer, and bladder cancer [48,51,52]. SMYD2 methylates H3K4 and H3K36 in 
vitro [113], and SMYD2-mediated H3K36me2 was reported to repress transcription of pro-
inflammatory cytokines IL-6 and TNF-α in macrophages [114]. However, inhibition or 
knockdown of SMYD2 does not change global H3K36 or H3K4 mono-, di-, or trimethylation, 
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and most of SMYD2 is found in the cytoplasm, suggesting SMYD2’s activity on chromatin may 
be minimal [115]. Indeed, SMYD2 methylates many non-histone substrates including p53, RB, 
HSP90, estrogen receptor α, and PARP1 [116–120], conveying wide-ranging effects on 
transcriptional regulation, protein homeostasis, apoptosis, and the DNA damage response. 
 The SETMAR gene evolved from fusion of a SET domain to a transposase domain [121]. 
As described above, the SETMAR protein has been linked to cancer via its role in DNA repair, 
which requires SETMAR’s KMTase activity [40]. In colon cancer SETMAR was further found 
to activate genes involved in repair, synthesis, and methylation of DNA, as well as stemness 
markers [122], but the contribution of KMTase activity to this function was not determined. 
Interestingly, purified SETMAR protein is not active on nucleosomes in vitro, raising the 
possibility that SETMAR may function by methylating non-histone substrates in vivo [42]. In 
addition, SETMAR undergoes automethylation near the active site of the transposase domain 
[123], but how automethylation regulates its DNA repair function is unknown.  
SETD3 is a poorly characterized putative tumor suppressor that methylates H3K4 and 
H3K36 in vitro and in SETD3-transfected cells [124]. SETD3 expression is lower in renal cell 
tumors than normal renal tissues, and low expression of SETD3 is associated with shorter 
survival in renal cell carcinoma patients [125]. SETD3 has been implicated in DNA replication 
and repair due to its interaction with proliferating cell nuclear antigen (PCNA), a conserved 
factor involved in DNA synthesis [126]. 
H3K36-specific SET domains: structural considerations for inhibitor development 
 
 Structural details of target proteins are extremely valuable in the development of potent 
and specific inhibitors. For the H3K36-specific KMTases, structural studies of the catalytic SET 
domain have revealed valuable information to jumpstart inhibitor development. An important 
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feature shared among the NSD, ASH1L, and SETD2 SET domains is an autoinhibitory loop 
blocking access of histone substrate to the active site [127–129]. This loop must undergo a 
conformational change to accommodate substrate binding. In contrast, structural studies of the 
more distantly related SMYD2 SET domain showed that substrate peptides bind this SET 
domain with minimal conformational changes [130,131].  
Structural studies of NSD, ASH1L, and SETD2 SET domains demonstrate feasibility of inhibitor 
design 
 
The SET domains of NSD1-3, ASH1L, and SETD2 consist of four subdomains: 
associated with SET (AWS), core SET, SET-insertion (SET-I), and post-SET (Figure 1.3A). 
AWS is a less structured region at the N-terminus that does not participate directly in catalysis, 
but the latter three subdomains contribute to the active site. The beta-sheet-rich core SET region 
is split by SET-I, a sequence-variable subdomain that has been proposed to play a role in 
substrate specificity [132]. Post-SET is a cysteine-rich subdomain that contains the 
autoinhibitory loop (Figure 1.3A). The methyl donor SAM binds in a pocket at the junction of 
core SET, SET-I, and post-SET, which make extensive contacts to SAM including hydrogen 
bonds and van der Waals contacts. Other important interactions involve tyrosine and carbonyl 
oxygens that form CH···O hydrogen bonds with the SAM methyl group [133].  
The autoinhibitory loop must undergo a significant conformational change to 
accommodate nucleosome substrate, and interestingly this loop undergoes dynamics even 
without nucleosome present. Molecular dynamics simulations, crystallographic, and NMR 
studies have shown that the NSD1 and ASH1L autoinhibitory loops experience conformational 
heterogeneity in the absence of nucleosome substrate [134,135]. In none of the observed 
conformations does the autoinhibitory loop completely open to allow nucleosome binding, 
suggesting that interaction with nucleosome is required to induce loop opening. Nevertheless, 
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conformational dynamics of the loop may be important for facilitating the larger conformational 
change that must occur upon nucleosome binding [134,135]. Interestingly, the autoinhibitory 
loop in the crystal structure of the related NSD3 SET domain is disordered [136], further 
suggesting that autoinhibitory loop dynamics are characteristic of the NSD and related SET 
domains. In the case of SETD2, both auto-inhibited and open conformations of the SET domain 
were observed by crystallography [129] (Figure 1.3B). When bound to S-adenosyl 
homocysteine (SAH), SETD2 adopts an autoinhibited conformation similar to NSD1 and 
ASH1L, with the sidechain of Arg1670 in the autoinhibitory loop extending into the putative 
substrate lysine binding channel (Figure 1.3B). In contrast, N-propyl sinefungin (Pr-SNF) was 
identified as a structural probe that replaces SAH and stabilizes an open conformation of SETD2 
(Figures 1.3B and C). Pr-SNF partially occupies the lysine binding channel and causes a 
dramatic conformational change in the autoinhibitory loop, as this loop moves away from core 
SET and Arg1670 flips 15 Å away from the lysine binding channel [129].  
The autoinhibitory loop region of the NSD and related KMTases provides an intriguing 
opportunity for H3K36 KMTase inhibitor development. The conformational heterogeneity 
observed in this region may create transient pockets not directly observed in crystal structures 
into which small molecules could bind. These ligands could function as allosteric inhibitors by 
preferentially interacting with and stabilizing the autoinhibited conformation of the SET domain. 
Importantly, the autoinhibitory loop is poorly conserved in primary sequence and in structure 
among NSD1, ASH1L, and SETD2 (Figures 1.3A and 1.4), suggesting that targeting this region 
could result in specific inhibitors for the different KMTases. In NSD1, the autoinhibitory loop is 
stabilized by a β-turn within the loop as well as hydrophobic contacts with SET-I [128]. In 
contrast, no β-turn exists in the ASH1L autoinhibitory loop, and there are longer range contacts 
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to SET-I [127,134]. In the SETD2 autoinhibitory loop, there is also no β-turn to stabilize the 
loop, but the interaction of Arg1670 at the beginning of the loop with the substrate lysine binding 
channel pulls the loop into contact with SET-I [129] (Figure 1.3B). Thus, the autoinhibitory loop 
region could be exploited for designing specific inhibitors of H3K36 KMTases.  
 
Figure 1.3. Structures and structural probes of H3K36 KMTases. (A) Overlay of the core SET 
(pale cyan), SET-I (sky blue), and post-SET (pale yellow) subdomains of NSD1 (PDB code 
3OOI), NSD3 (4YZ8), ASH1L (4YNM), and SETD2 (4H12). The structurally variable 
autoinhibitory loop region is colored in red. (B) Binding of the Pr-SNF inhibitor to SETD2 
causes opening of the autoinhibitory loop. Autoinhibitory loop conformation is shown with SAH 
bound (pale yellow, 4H12) and with Pr-SNF bound (magenta, 4FMU). Steric clash between the 
propyl moiety of Pr-SNF (cyan) and the Arg1670 sidechain (orange) causes Arg1670 to flip out 
a distance of 15 Å. Residues stabilizing Arg1670 in the putative substrate lysine binding channel 
in the SAH-bound form of SETD2 are shown in pale yellow sticks. (C) Chemical structures of 
SETD2 inhibitors sinefungin and Pr-SNF. In vitro IC50 values for SETD2 are listed. 
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Figure 1.4. Sequence alignment of core SET and post-SET regions of the related NSD, ASH1L, 
and SETD2 KMTases. Blue lines indicate conserved contacts to SAM cofactor. Black box 
indicates the autoinhibitory loop, black line indicates post-SET subdomain. 
 
SMYD2 structures: U-shaped substrate binding 
 
 Crystal structures of full-length SMYD2 show an overall structure of two lobes or 
domains separated by a deep groove (Figure 1.5A). The N-terminal lobe contains the core SET 
region surrounded by a MYND zinc finger, the SET-I subdomain, and the cysteine-rich post-
SET subdomain. The C-terminal domain (CTD) is made up of seven anti-parallel α-helices in a 
structure reminiscent of the tetratricopeptide repeat (TPR), a motif involved in protein-protein 
interactions. The CTD regulates KMTase activity of the SET domain, possibly via interactions 
the CTD forms with the substrate protein [130]. The CTD also controls activity and substrate 
specificity via an interaction with the SMYD2 cofactor Hsp90 [113,137]. The SAM cofactor 
binds in the crevasse between the N- and C-terminal lobes and makes direct contacts with core 
SET, SET-I, and post-SET (Figure 1.5A). Regulatory cross-talk between the CTD and SET 
domain active site was suggested by the observation that binding of the SAM analog sinefungin 
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induces a long range conformational change in the first two α-helices of the CTD, resulting in a 
more open conformation of SMYD2 [137,138].  
 Ternary complexes of SMYD2 have been solved with SAM and p53 peptide, SAH and 
methylated p53 peptide, and SAM and ERα peptide (Figure 1.5A). The p53 and ERα peptides 
bind in a U-shaped conformation at the hinge region between the N- and C-terminal lobes, with 
the target lysine at the base of the “U” [130,131,139]. The target lysine projects deep into a 
hydrophobic cavity, with the lysine ε-amino group oriented by the hydroxyl groups of two 
conserved tyrosine residues and several main chain carbonyl groups. Although the CTD does not 
directly interact with SAM cofactor, residues from the CTD are involved in binding to substrate 
peptides. Remarkably, given the narrow groove between the N and C-terminal lobes and the 
previously described flexibility in the CTD, only minor structural changes in SMYD2 occur 
upon binding to substrate peptides [130,131].  
Inhibitors of H3K36 methyltransferases 
 
 Inhibitors for two members of the H3K36 methyltransferases, SETD2 and SMYD2, have 
been reported. Zheng et al. developed N-propyl sinefungin (Pr-SNF) and N-benzyl sinefungin, 
analogs of the broad-spectrum KMTase inhibitor sinefungin, as specific inhibitors of SETD2. Pr-
SNF and N-benzyl sinefungin inhibit SETD2 KMTase activity in vitro with IC50 values of 0.8 
μM and 0.5 μM, respectively (Figure 1.3C). These values represent activities more than 10-fold 
better than unmodified sinefungin, and with at least 2-fold selectivity over a panel of related 
KMTases. A co-crystal structure of SETD2 in complex with Pr-SNF revealed that the N-propyl 
moiety partially occupies the lysine binding channel and causes a dramatic conformational 
change in the autoinhibitory loop [129]. No activity for Pr-SNF has been reported in cells, and 
sinefungin analogs in general have poor cell membrane permeability. Nevertheless, combined 
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occupancy of the SAM and substrate lysine binding pockets by small molecules is an intriguing 
strategy that warrants further study in other KMTases. 
The first specific SMYD2 inhibitor, AZ505, was discovered using an AlphaLISA-based 
high throughput screen of 1.23 million compounds from the Astra Zeneca library [131] (Figure 
1.5B). The compound binds with Kd of 0.5 μM to the peptide binding groove of SMYD2 and is 
greater than 100-fold selective over related KMTases including SMYD3. The AZ505 binding 
site partially overlaps with that of p53 peptide (Figure 1.5C). Interestingly, the benzooxazinone 
moiety of AZ505 occupies the substrate lysine binding channel, indicating that this channel may 
accommodate much larger and more rigid groups than a lysine sidechain. The cyclohexyl group 
of AZ505 is positioned in a hydrophobic pocket occupied by Leu369 of the p53 peptide. 
However, the dichlorophenethyl group of AZ505 extends into a second hydrophobic pocket that 
is not occupied by the p53 substrate peptide. 
 AZ505 was optimized to improve potency while retaining cellular permeability. Nguyen 
et al. developed the SMYD2 inhibitor LLY-507 by making substantial changes to AZ505, using 
a pyrrolidine group rather than benzooxazinone to occupy the substrate lysine binding channel 
(Figures 1.5B and C). LLY-507 inhibits SMYD2 methyltransferase activity in an in vitro assay 
with IC50 < 15 nM but maintains an excellent selectivity profile over other KMTase and non-
KMTase enzymes. LLY-507 inhibits p53 methylation in HEK293 and U2OS cells 
overexpressing SMYD2 and/or p53, and the compound inhibits proliferation of esophageal 
squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and breast cancer cell lines 
[115]. 
A second SMYD2 inhibitor, A-893, was also inspired by the AstraZeneca HTS hit but 
makes fewer changes to the AZ505 scaffold (Figures 1.5B and C). A-893 inhibits SMYD2 
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KMTase activity in vitro with an IC50 of 2.8 nM and blocks p53 methylation in the A549 lung 
carcinoma cell line. This large increase in activity over AZ505 was achieved by moving a 
hydroxyl group from the benzooxazinone to the diethylamine linker. The increase in potency is 
likely mediated by a hydrogen bond that the relocated hydroxyl group forms with the backbone 
carbonyl of Tyr240 [140]. 
 
 
Figure 1.5. Peptide substrate-competitive inhibitors of the SMYD2 KMTase. (A) Crystal 
structure of SMYD2 bound to p53 peptide (PDB code 3TG5). (B) Chemical structures of 
SMYD2 inhibitors. (C) Overlay of binding modes of SMYD2 inhibitors LLY-507 (4WUY) and 
A-893 (4YND) and p53 peptide. The weaker compound AZ505 binds to the same site but has 
been omitted for clarity. SAM position included for reference.   
 
Challenges and opportunities in developing specific inhibitors of H3K36 KMTases 
 
Targeting the catalytic SET domain  
The H3K36 KMTases are highly relevant to biology and medicine, and development of 
potent and specific inhibitors for this class of proteins is urgently needed. However, very few 
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specific inhibitors of H3K36 KMTases have been reported, highlighting difficulties associated 
with this target class. First, developing in vitro methylation assays for H3K36 KMTases can be 
challenging because the SET domain may require chromatin-interacting domains and/or co-
factor proteins for optimal activity on nucleosome substrate. For example, the isolated ASH1L 
SET domain has weak KMTase activity on nucleosomes, but constructs including the PHD, 
Bromo, and BAH domains have increased activity [134]. An additional obstacle is that inhibitors 
of KMTases appear to be rare in current high-throughput screening (HTS) libraries, as three 
different pharmaceutical companies published SAM-competitive inhibitors of the EZH2 
KMTase with similar pyridone-containing scaffolds [11]. KMTase-privileged screening libraries, 
which could be based on known KMTase inhibitors like sinefungin and chaetocin [129,141], 
may help increase the number of screening hits. 
In contrast to screening through large compound libraries, a more focused approach to 
developing KMTase inhibitors could proceed by modifying the SAM cofactor. Structural 
chemical analysis of ten different human KMTase SET domains suggested that the SAM binding 
pocket represents a druggable region because a low proportion of the SAM molecular surface is 
accessible to solvent when bound to the SET domain. Moreover, although the conformation of 
bound SAM cofactor is very similar across different SET domains due to a precise hydrogen 
bond network, SAM binding pockets contain enough structural diversity surrounding this 
network to allow development of specific inhibitors for different KMTases [142]. Indeed, 
chemical modification of SAM or closely related compounds like sinefungin has led to potent 
and specific inhibitors for several KMTases [129,143,144]. An additional consideration for 
designing SAM-derivative inhibitors is that the SAM binding pocket is immediately adjacent to 
the narrow substrate lysine binding channel. Therefore, weak or non-specific SAM derivatives 
26 
 
may be improved to target a specific KMTase by adding hydrophobic groups that interact with 
the lysine binding channel. Proof of principle for this hypothesis was demonstrated by sinefungin 
analogs that specifically inhibit SETD2 [129]. The potency of SAM-derivative inhibitors could 
be further enhanced by including moieties that mimic the transition state for the methyl transfer 
reaction, as enzyme theory predicts that KMTases should bind the transition state more tightly 
than the individual SAM and histone substrates [145]. Kinetic isotope effects were recently used 
to generate a model of the NSD2 transition state, providing an opportunity for development of 
transition state mimics [146]. Thus far, poor membrane permeability of the available SAM-
derivative inhibitors has proven a challenge in applying these compounds to cellular systems 
[147]. 
Alternative druggable regions of H3K36 KMTase proteins 
 Most H3K36-specific KMTases are large epigenetic regulators that contain multiple 
protein-protein interacting (PPI) domains in addition to the catalytic SET domain. In a growing 
number of cases, PPI domains of KMTase proteins have been found essential for recruiting the 
SET domain to its methylation targets. PPI domains may also have SET domain-independent 
oncogenic roles. Structural studies have revealed that PPI domains could be highly druggable 
targets [148,149]. Therefore, to overcome challenges associated with inhibitor development for 
H3K36 SET domains, an alternative approach is to target the PPI domains.   
 For example, PPI domains of NSD2 are essential for the protein’s oncogenic activity. The 
N-terminal PWWP domain of NSD2 preferentially binds H3K36me2 and is important for 
recruiting NSD2 to its target genes [7]. Point mutations in the PWWP domain that prevent 
recognition of methyllysine inhibit NSD2’s ability to increase H3K36 methylation and cancer 
cell proliferation. The fact that the NSD2 PWWP domain recognizes the same mark produced by 
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the NSD2 SET domain suggests a role for the PWWP domain in spreading H3K36 dimethylation 
to neighboring genomic regions and to daughter cells during DNA replication [7]. NSD2 also 
contains four PHD domains, a family of epigenetic reader modules that bind methylated lysines 
on H3 [150]. The NSD2 PHD domains are required for epigenetic changes and oncogenic 
activity mediated by NSD2 due to their role in recruiting NSD2 to chromatin [47,151]. Structural 
studies have shown that PWWP and PHD domains interact with histone via an aromatic cage 
that surrounds methyllysine, as well as a hydrogen bonding network with nearby histone residues 
(Figure 1.6A and B) [148,149]. Although no well validated inhibitors of PWWP or PHD 
domains have yet been reported, the histone-binding surface of these domains provides 
opportunities for development of small molecules that compete with histone [150,152]. 
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Figure 1.6. Targeting PPI domains of H3K36 KMTases as an alternative to the SET domain. 
Examples of PHD and PWWP domains: (A) Third PHD domain of MLL1 (cyan) bound to 
H3K4me3 peptide (green) (PDB code 3LQJ) and (B) PWWP domain of ZMYND11 (cyan) 
bound to H3.3K36me3 peptide (green) (4N4I). Residues on the PPI domain that form the 
aromatic cage are colored magenta. (C) PPI regions in the N-terminus of NSD3 that are required 
for leukemogenesis, adapted with permission from [6]. 
 
In some cases, KMTase proteins may engage in PPIs that drive oncogenesis 
independently of the SET domain. For example, recent studies have shown that NSD3 engages in 
a rich repertoire of PPIs with other chromatin readers and remodelers. In a subset of NUT 
midline carcinoma (NMC) cases, an NSD3-NUT fusion protein, which lacks the NSD3 SET 
domain, blocks differentiation [153]. The NSD3 N-terminus in the fusion protein interacts with 
the bromodomain-containing protein BRD4 to drive oncogenesis, and NSD3-NUT NMC cells 
are sensitive to the bromodomain inhibitor JQ1. In addition, wild-type NSD3 is required for 
proliferation of NMC cells harboring a BRD4-NUT fusion protein, demonstrating that the 
NSD3/BRD4 interaction is key to the pathogenesis of NMC in general [153]. The interaction 
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between NSD3 and BRD4 was further characterized in AML, in which a short isoform of NSD3 
lacking the SET domain drives leukemogenesis by serving as a bridge between BRD4 and the 
chromatin remodeler CHD8. An N-terminal transactivation domain and PWWP domain are also 
necessary for NSD3 to activate transcription and maintain leukemia (Figure 1.6C) [6]. Thus, in 
some contexts PPIs rather than KMTase activity are key to NSD3’s oncogenic role.  
These studies reveal that H3K36 KMTases harbor a variety of potentially druggable 
domains and regions in addition to the SET domain. Precise targeting of individual domains with 
small molecule inhibitors will ideally leave other protein functions unaffected and may reveal 
highly specific cancer dependencies. On the other hand, in some cases the entire KMTase protein 
may need to be eliminated to achieve anti-cancer activity. To overcome this challenge, one could 
use small molecule ligands capable of targeting proteins for proteolytic degradation [154,155]. 
For example, Winter et al. have recently found that coupling a ligand of a target protein to 
phthalimide results in engagement of the cellular ubiquitin ligase machinery and degradation of 
the target protein [154]. This method could be applied to KMTases, such that phthalimide 
conjugates of KMTase ligands could be used to degrade an entire KMTase protein. 
Conclusions and future perspectives 
 The H3K36-specific KMTases are prominent drug targets due to numerous studies 
linking them to oncogenesis. However, large knowledge gaps remain surrounding the 
mechanisms by which H3K36-specific KMTases drive cancer growth, whether it is by 
controlling transcription, splicing, DNA repair, or other cellular processes. Small molecule 
inhibitors for H3K36-specific KMTases will be invaluable chemical tools to better understand 
the role of these proteins in cancer. Developing potent and specific inhibitors for this challenging 
target class will require creative and non-traditional approaches. Derivatives of SAM and 
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sinefungin have shown promise as specific inhibitors of KMTases and this compound class could 
be further expanded to cover H3K36-specific KMTases. In addition, the autoinhibitory loop is a 
unique feature of H3K36-specific SET domains that could be exploited for inhibitor 
development. Furthermore, some PPI domains of KMTase proteins are required for oncogenic 
functions and provide excellent opportunities for targeting by small molecules. Major progress 
on the structure and function of H3K36 KMTases in recent years leads us to predict that the 
KMTase inhibitor field lies on the precipice of many innovative and exciting discoveries. 
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Chapter 2. Two loops undergoing concerted dynamics regulate activity of the ASH1L histone 
methyltransferase

 
 
Abstract 
 
ASH1L (absent, small, or homeotic-like 1) is a histone methyltransferase (KMTase) 
involved in gene activation that is overexpressed in multiple forms of cancer. Previous studies of 
ASH1L’s catalytic SET domain identified an autoinhibitory loop that blocks access of histone 
substrate to the enzyme active site. Here, we used both NMR and X-ray crystallography to 
identify conformational dynamics in the ASH1L autoinhibitory loop. Using site-directed 
mutagenesis we found that point mutations in the autoinhibitory loop that perturb the structure of 
the SET domain result in decreased enzyme activity, indicating that the autoinhibitory loop is not 
a simple gate to the active site but is rather a key feature critical to ASH1L function. We also 
identified a second loop in the SET-I subdomain of ASH1L that experiences conformational 
dynamics, and we trapped two different conformations of this loop using crystallographic 
studies. Mutation of the SET-I loop led to a large decrease in ASH1L enzymatic activity in 
addition to a significant conformational change in the SET-I loop, demonstrating the importance 
of the structure and dynamics of the SET-I loop to ASH1L function. Furthermore, we found that 
three C-terminal chromatin-interacting domains greatly enhance ASH1L enzymatic activity and 
that ASH1L requires native nucleosome substrate for robust activity. Our study illuminates the 
role of concerted conformational dynamics in ASH1L function and identifies structural features 
important for ASH1L enzymatic activity. 
                                                          
 Rogawski DS, Ndoj J, Cho HJ, Maillard I, Grembecka J, Cierpicki T. Two Loops Undergoing Concerted 
Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase. Biochemistry 54(35), 5401-13 (2015). 
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Introduction 
ASH1L (absent, small, or homeotic-like 1) is a mammalian homolog of Ash1, a member 
of the trithorax group of proteins essential for epigenetic mechanisms of gene activation [156]. 
ASH1L is a SET domain-containing histone methyltransferase (KMTase) with controversial 
substrate specificity. ASH1L was shown to methylate H3K4 [157,158] and H3K36 
[44,93,127,159,160] in mammals. Although the specificity of the SET domain and function of 
ASH1L in vivo are not yet clear, emerging data link ASH1L to multiple cancers. In breast 
cancer, 27 percent of aggressive, basal-like breast cancers have high-level copy number 
amplifications of the ASH1L gene [161]. Moreover, high levels of ASH1L mRNA are associated 
with shorter survival in breast cancer patients [161]. In thyroid cancer, ASH1L is overexpressed 
in tumor-specific truncated forms and is downregulated by a tumor suppressor microRNA [94]. 
Amplifications of ASH1L are found in a variety of other tumors, such as lung and uterine cancer 
[162,163], while mutations in ASH1L have been identified in gastric cancer [164], colorectal 
cancer [165], esophageal squamous cell cancer [166], and lung cancer [167]. ASH1L activates 
genes in the HOX-A, HOX-B, and HOX-C clusters [15,88], which are overexpressed in multiple 
cancers and correlated with metastasis and aggressive disease [89]. Notably, ASH1L activates 
HOXA9 and its collaborator MEIS1 [15], which are oncogenes in leukemia [168]. 
The ASH1L protein has a large and unannotated N-terminus, a SET domain responsible 
for KMTase activity, and three C-terminal chromatin-interacting domains: bromodomain, plant 
homeodomain (PHD), and bromo-associated homology (BAH) domain [93]. ASH1L’s catalytic 
SET domain is required for its gene activating function, as deletion of the ASH1L SET domain 
in differentiating mouse embryonic stem cells leads to a decrease in expression of multiple 
genes, including members of the Wnt and Hox families [93]. Most SET domains including 
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ASH1L SET can be divided into four subdomains: associated with SET (AWS), core SET, post-
SET, and the variable SET-I subdomain positioned in the middle of core SET, which is a 
putative substrate specificity cassette for KMTases [132]. In ASH1L and the closely related 
NSD1 and SETD2 KMTases, a region in the post-SET subdomain called the autoinhibitory loop 
blocks access of histone substrate to the enzyme active site [127–129]. It is unclear how the 
autoinhibitory loop reorients to accommodate substrate binding, as the structures for ASH1L, 
NSD1, and SETD2 were determined in the absence of histone substrate. Furthermore, whether 
the autoinhibitory loop functions simply as a gate to the active site or whether it forms important 
interactions with nucleosome substrates is unknown. In the case of NSD1, molecular dynamics 
simulations showed modest flexibility of the NSD1 autoinhibitory loop that may permit the 
H3K36 sidechain to access NSD1’s lysine binding channel [128], but this computational study 
was not confirmed experimentally. In the case of SETD2, an open and substrate-accessible 
conformation of the autoinhibitory loop was observed by crystallographic studies upon binding 
of N-propyl sinefungin, which forces reorientation of Arg1670 that normally occupies the 
substrate lysine binding channel [129]. Even less is known about the function of the 
autoinhibitory loop of ASH1L. In the ASH1L SET domain crystal structure, high B factors for 
the autoinhibitory loop led the authors to conclude that this loop is highly mobile [127]. The 
functional significance of this mobility in solution, however, remains unclear. Interestingly, a 
Q2265A ASH1L mutant with increased catalytic activity had a highly disordered autoinhibitory 
loop by preliminary structural analysis, suggesting that destabilization of the autoinhibitory loop 
might be sufficient to increase ASH1L enzymatic activity [127]. 
Here we aimed to better understand the function of ASH1L by investigating structural 
features of the ASH1L SET domain and assessing how they regulate its KMTase activity. Using 
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X-ray crystallography and NMR we found that two loops surrounding the active site of 
ASH1L—the autoinhibitory loop and a loop in the SET-I subdomain—undergo concerted 
conformational dynamics. We designed several mutations in the SET domain to perturb the 
conformation of these loops and characterized the structure and activity of the mutants. We 
found that the autoinhibitory loop is not a simple gate blocking access to the active site. Instead, 
the autoinhibitory loop and the SET-I loop represent important structural features required for 
ASH1L SET domain activity. Moreover, our study emphasizes that concerted dynamics play a 
significant role in ASH1L KMTase activity. These results shed light on the mechanisms of SET 
domain function and may provide a foundation for development of ASH1L inhibitors. 
Results 
Crystal structure of the ASH1L SET domain shows increased dynamics of the autoinhibitory and 
SET-I loops  
 
To gain insight into the mechanism of methyltransferase activity by ASH1L, we 
determined the crystal structure of the ASH1L SET domain (residues 2069-2288) (Figure 2.1A). 
The crystals diffracted to 2.2 Å resolution, representing a significant improvement over the 
previously published 2.9 Å structure of the ASH1L SET domain [127]. Higher resolution 
allowed us to more precisely model residues throughout the structure, including regions 
associated with the catalytic activity of ASH1L. We observed satisfactory electron density for 
the main chain and for the majority of sidechains in the autoinhibitory loop (residues 2258-2266) 
(Figure 2.1B). The poor electron density for some sidechains suggested that the autoinhibitory 
loop may experience conformational dynamics, and to further evaluate dynamics of the SET 
domain we used crystallographic B factors. We found that the autoinhibitory loop and the AWS 
region have the highest B factors, suggesting that these are more mobile regions (Figure 2.1C). 
Interestingly, we also found that the SET-I subdomain has higher B factors than the neighboring 
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C-terminal core SET region (SET-C) (Figure 2.1C). The SET-I subdomain consists of a helix-
loop-strand-turn-strand motif, with the SET-I loop (residues 2187-2195) in this motif located 
directly beneath the autoinhibitory loop (Figure 2.1D). Residues 2192-2194 in the SET-I loop 
make both polar and hydrophobic contacts with S-adenosyl methionine (SAM) cofactor. We 
observed well-defined electron density for SET-I residues, with the exception of the sidechain of 
His2193, which is poorly defined, indicating that this residue may undergo conformational 
exchange (Figure 2.1D). 
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Figure 2.1. Analysis of ASH1L SET domain crystal structure. (A) Cartoon representation of the 
ASH1L SET domain, colored by subdomain: N-terminus, grey; AWS, magenta; core SET, cyan; 
SET-I, blue; post-SET, dark yellow. (B) The autoinhibitory loop of ASH1L with mFo-DFc omit 
map contoured at 2.5σ. Subdomains colored as in (A). (C) Normalized crystallographic B factors 
for the ASH1L SET domain. (D) The SET-I loop of ASH1L with mFo-DFc omit map contoured 
at 2.5σ. Subdomains colored as in (A).  
 
NMR studies reveal that the ASH1L active site is surrounded by two loops experiencing 
conformational dynamics  
 
To further investigate the dynamics of the ASH1L SET domain we performed NMR 
studies in solution. We collected a 
15
N-
1
H TROSY NMR spectrum for the ASH1L SET domain. 
While the ASH1L SET construct contains 213 non-proline residues, we observed only 181 
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backbone amide peaks in the NMR spectrum. The large number of missing peaks suggested that 
a significant portion of the protein is undergoing intermediate exchange dynamics on the 
microsecond-millisecond timescale [169,170]. To identify the regions undergoing such 
dynamics, we completed backbone assignment based on triple resonance experiments for 
15
N
13
C-
labeled ASH1L (Figure 2.2A). We were able to assign 168 (93%) of the 181 peaks observed for 
backbone amides. Interestingly, we were not able to observe any backbone amide peaks for 
residues in the autoinhibitory loop and in a large portion of the SET-I subdomain including the 
entire SET-I loop, while we obtained nearly complete assignment for the remaining part of the 
SET domain (Figure 2.2A and B). This observation strongly suggests that the autoinhibitory and 
SET-I loops surrounding the active site of ASH1L experience conformational dynamics, in 
agreement with crystallographic data presented above. Interestingly, while the crystallographic 
B-factors for the AWS subdomain are very high, we observe nearly all the AWS residues in the 
NMR spectrum (Figure 2.2C), suggesting that in solution the AWS subdomain undergoes 
dynamics at a much faster time scale than the SET-I loop and autoinhibitory loop. Overall, we 
concluded that two loops surrounding the active site of ASH1L, the autoinhibitory loop and 
SET-I loop, are undergoing dynamics in solution on the microsecond-millisecond timescale.   
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Figure 2.2. NMR studies of the ASH1L SET domain. (A) 
15
N-
1
H TROSY spectrum of ASH1L 
SET domain with assignment. Right panel shows zoomed in view of the central region of the 
spectrum. (B) NMR assignment mapped onto ASH1L SET domain crystal structure. Residues 
with assigned peaks in the TROSY spectrum are magenta, while unassigned residues are cyan. 
(C) Cartoon putty representation of ASH1L with thickness of cartoon directly proportional to B 
factor. Assigned and unassigned residues colored as in (B). 
 
ASH1L requires chromatin-interacting domains for robust enzymatic activity  
We next aimed to develop a robust assay to measure the catalytic activity of ASH1L. A 
previous study showed weak catalytic activity for the isolated SET domain of ASH1L [93]. We 
tested the catalytic activity of ASH1L SET in a radiometric KMTase assay with different 
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substrates including chicken nucleosomes and detected weak activity using 1 μM ASH1L SET 
construct (Figure 2.3A) and 0.8 μM nucleosome (Figure 2.3B, inset). Because full-length 
ASH1L is a large multi-domain protein with three chromatin-interacting domains at its C 
terminus (a bromodomain [171], a PHD finger [172], and a BAH domain[173]) (Figure 2.3A), 
we wondered whether these domains would enhance ASH1L KMTase activity. 
To investigate the effect of the chromatin-interacting domains on ASH1L KMTase 
activity, we designed three additional ASH1L constructs of different lengths systematically 
incorporating the chromatin reader domains at the C-terminus of the protein (Figure 2.3A). We 
tested the enzymatic activity of the different ASH1L constructs using 0.25 μM ASH1L and 0.2 
μM chicken mono/di nucleosome substrate. We found that the isolated SET domain has no 
detectable KMTase activity on chicken nucleosome substrate under these assay conditions 
(Figure 2.3B). A larger construct incorporating the N-terminal flanking region of the SET 
domain (N-SET)[93] also had very low activity (Figure 2.3B). In contrast, the SET-PHD and 
SET-BAH constructs had significantly higher KMTase activity, with the longest construct SET-
BAH being most active (Figure 2.3B). These results show that chromatin-interacting domains 
are necessary for robust enzymatic activity of ASH1L, likely through recruitment of nucleosome 
substrates. Despite significantly enhanced activity we were not able to characterize kinetic 
parameters for ASH1L because the signal was too weak at the low nanomolar enzyme 
concentrations required to accurately determine the Michaelis constants. 
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Figure 2.3. Enzymatic activity of ASH1L variants. (A) Schematic of ASH1L variants tested in 
the enzymatic assay. (B) Activity in counts per minute (CPM) of ASH1L constructs with chicken 
mono/di nucleosome substrate at 0.25 μM ASH1L and 0.2 μM nucleosome. Inset: activity of 
ASH1L SET at 1 μM enzyme and 0.8 μM nucleosome. (C) Activity of ASH1L SET-BAH 
construct with various native and recombinant nucleosome substrates at 0.2 or 0.4 μM 
concentration. (D) Sequence alignment of the autoinhibitory loop of human ASH1L with related 
KMTases. Sites selected for mutagenesis are shown with arrows. (E) Location of residues 
selected for mutagenesis (magenta). (F) Activity of ASH1L SET-BAH WT and mutant proteins 
on chicken mono/di nucleosomes using 0.25 μM ASH1L and 1.7 μM chicken mono/di 
nucleosomes. 
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ASH1L SET-BAH requires native nucleosome substrate for optimal enzymatic activity  
Previous studies have shown that ASH1L requires nucleosomes as substrate [93,127], 
and a recent study by Eram et al. showed enhanced activity of the ASH1L SET domain on native 
chicken nucleosomes compared to recombinant, reconstituted nucleosomes [160]. We tested 
whether our longer, most active ASH1L SET-BAH construct also has enhanced activity on 
native versus recombinant nucleosomes. We found that, indeed, SET-BAH had much higher 
activity on native nucleosomes (Figure 2.3C). Interestingly, among the native nucleosomes we 
tested, ASH1L SET-BAH exhibited nearly twofold higher activity on chicken mono/di-
nucleosomes than HeLa nucleosomes and chicken oligonucleosomes at 0.2 μM nucleosome 
concentration (Figure 2.3C). Taken together with the results of Eram et al., our studies indicate 
that ASH1L exhibits greater activity on native nucleosomes, and this may be partly due to 
recognition of covalent modifications on native nucleosomes through the chromatin-interacting 
domains of ASH1L.  
Mutations of non-conserved residues in autoinhibitory loop have significant effects on ASH1L 
SET domain activity  
 
A previous study suggested that the autoinhibitory loop of ASH1L regulates its KMTase 
activity, likely by physically blocking access to the active site [127]. On the other hand, our 
results indicated that the autoinhibitory and SET-I loops surrounding the active site of the SET 
domain experience significant dynamics in solution. In addition, sequence analysis of SET 
domains related to human ASH1L indicate that residues in the autoinhibitory loop are not 
conserved (Figure 2.3D). We aimed to dissect the contribution of different residues in the 
autoinhibitory loop to the enzymatic activity of ASH1L by making a series of point mutations 
based on our crystal structure of the SET domain (Figure 2.3E). We explored rather severe 
mutations with the overall goal to affect the conformation of the autoinhibitory loop while 
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avoiding global disruption of the SET domain. 
In an attempt to destabilize the autoinhibitory loop, we mutated His2258 to Asp to 
introduce electrostatic repulsion with two adjacent acidic residues, Glu2225 and Asp2254 
(Figure 2.3E). Interestingly, we found that the H2258D mutant exhibited a modest ~30% 
decrease in activity (Figure 2.3F), suggesting that electrostatic interactions involving His2258 
play a minor role in regulating enzyme activity. Next we investigated the neighboring residue 
Ser2259, whose sidechain points toward the S-methyl group of SAM cofactor. Crystallographic 
studies of the related SETD2 KMTase suggested that the amino acid occupying this position 
could play a key role in flipping the autoinhibitory loop from a closed to open conformation 
[129]. To investigate the regulatory potential of Ser2259 we mutated it to Met to enhance 
hydrophobic contacts with core SET and SET-I. We found that the S2259M mutation strongly 
decreased ASH1L activity by ~90% (Figure 2.3F), consistent with an important regulatory role 
for Ser2259. 
In the middle of the autoinhibitory loop, Val2262 forms hydrophobic contacts with 
Phe2179 and Met2183 in SET-I. To explore the role of these contacts, we mutated Val2262 to 
Asp. We found that the V2262D mutation caused nearly no effect on enzymatic activity 
compared to wild-type ASH1L (Figure 2.3F). This result suggests that the hydrophobic contacts 
made by Val2262 are not critical for enzymatic activity. The result is also consistent with the 
dynamic nature of the autoinhibitory loop, which may contact SET-I in only a subset of its 
heterogeneous conformations. 
At the end of the autoinhibitory loop, we tested whether we could stabilize the 
autoinhibited form of the SET domain by mutating Lys2264 to Leu and thereby enhance 
hydrophobic contacts between the autoinhibitory loop and SET-I. The K2264L mutation 
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decreased activity by ~50% (Figure 2.3F), which is consistent with a need for polar residues at 
this position based on sequence alignment to related methyltransferases (Figure 2.3D). Finally, it 
was previously reported that mutation of the solvent-exposed Gln2265 to Ala results in 
enhancement of ASH1L activity, likely through destabilization of the autoinhibitory loop [127]. 
To further explore this finding we introduced the Q2265A mutation into the SET-BAH construct 
and found that indeed its activity is increased by ~50% compared to wild type (Figure 2.3F). 
Altogether, we found that despite their low-level conservation, the mutated autoinhibitory loop 
residues confer significant regulatory control over ASH1L enzyme activity. Our results suggest 
that the ASH1L autoinhibitory loop is a precisely tuned structural feature with a more complex 
role than simply blocking the active site.  
NMR studies correlate the degree of structural perturbation to enzyme activity  
We used NMR to assess structural perturbations to the ASH1L SET domain caused by 
the autoinhibitory loop mutations. For these studies we selected four mutants: S2259M, V2262D, 
K2264L, and Q2265A. We collected 
15
N-
1
H TROSY spectra for all four variants and mapped the 
chemical shift perturbations caused by the mutations onto the ASH1L crystal structure (Figure 
2.4A-D). We found that both the S2259M and K2264L mutations caused perturbations to an area 
surrounding the dynamic autoinhibitory loop region of the protein (Figure 2.4A and B). The 
S2259M mutation caused chemical shift perturbations mostly in β-sheets in the SET-I region and 
core SET region that contact the autoinhibitory loop (Figure 2.4A). The K2264L mutation 
caused a greater number of perturbations in a complete shell surrounding the autoinhibitory loop 
(Figure 2.4B). In addition to the β-sheets affected by S2259M, the perturbed shell includes the 
SET-I helix and the C-terminal tail of the post-SET region, which are located above and below 
the autoinhibitory loop, respectively.  The widespread chemical shift perturbations caused by 
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single amino acid substitutions in the autoinhibitory loop suggest regulatory cross-talk between 
the autoinhibitory loop and the rest of the SET domain. 
Interestingly, we found that the Q2265A mutation, which was previously reported to 
destabilize the substrate-unbound conformation of the autoinhibitory loop [127], led to very few 
chemical shift perturbations on the NMR spectrum of ASH1L (Figure 2.4C). Chemical shift 
perturbations were limited mostly to a small local area immediately adjacent to the Q2265A 
mutation, including residues in the post-SET subdomain. Finally, the V2262D mutation, which 
had nearly no effect on enzyme activity, also had a relatively small effect on the structure of the 
SET domain as determined by NMR chemical shift perturbations (Figure 2.4D). Notably, we did 
not observe an increase in the total number of signals observed in the 
15
N-
1
H TROSY spectra for 
any of the mutants. Therefore, none of these mutations significantly alter the intermediate 
exchange dynamics in the autoinhibitory and SET-I loops. 
In summary, our NMR analysis showed that mutations leading to large decreases in 
enzyme activity (S2259M and K2264L) caused significant structural perturbations throughout 
the SET domain. In contrast, mutations that had no effect or caused enhanced activity (V2262D 
and Q2265A) caused only small perturbations to the SET domain as measured by chemical shift 
perturbations (Figure 2.4A-E). These results suggest that the proper structure and dynamic 
properties of the ASH1L autoinhibitory loop are required for enzyme activity.  
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Figure 2.4. Effects of autoinhibitory loop mutations in ASH1L. (A-D) Chemical shift 
perturbations (Δ, see Methods) of backbone amides in TROSY spectra induced by S2259M (A), 
K2264L (B), Q2265A (C), and V2262D (D) mutations mapped on the crystal structure of wild-
type ASH1L SET domain. Residues perturbed by Δ < 10 Hz, grey; 10 ≤ Δ < 20 Hz, orange; Δ ≥ 
20 Hz, red; unassigned, cyan. Mutated residues are labeled and shown in green. The sum of all 
chemical shift perturbations (Δsum) is shown for each mutant. (E) A region of the TROSY spectra 
showing greater chemical shift perturbations caused by the K2264L and H2193F mutants. (F), 
(H), (I) Comparison of autoinhibitory loop conformation between the mutants (S2259M in 
yellow (F), K2264 in magenta (H), Q2265A in green (I)) and wild type ASH1L (grey), with 
2mFo-DFc maps for the mutants contoured at 0.8σ. (G) Mutant Met2259 partially occupies 
substrate lysine binding channel. Post-SET subdomain depicted as cartoon, all other regions 
depicted as surface. Residues His2193, Tyr2194, Cys2195, Leu2196, Tyr2253, and Tyr2255 that 
form the substrate lysine binding channel are highlighted in magenta.  
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Mutations affect structure and mobility of the ASH1L autoinhibitory loop  
Next we determined the crystal structures of the ASH1L SET domain mutants that caused 
the largest changes in activity: S2259M, K2264L, and Q2265A. After refinement of these 
structures, the Rfree statistic remained high (Table 2.1), primarily due to the more flexible AWS 
subdomain. Compared to the WT structure, the S2259M structure showed modest changes to 
autoinhibitory loop sidechains (Figure 2.4F). However, the sidechain of Met2259 in the mutant 
protrudes into a channel bordered by the backbone atoms of His2193, Tyr2194, and Cys2195 and 
the sidechains of Leu2196, Tyr2253, and Tyr2255, which is the putative substrate lysine binding 
site (Figure 2.4F, G). The Met2259 sidechain methyl group is a close 4.4 Å distance from the S-
methyl group of SAM. These data indicate that the profound reduction in activity of the S2259M 
mutant (Figure 2.3F) is likely caused by stabilization of the inactive conformation of the SET 
domain via interaction of the methionine sidechain with the substrate lysine binding channel. 
Therefore, our findings suggest that Ser2259 is an important gatekeeper residue that partially 
occupies the lysine binding channel in the autoinhibited conformation of the SET domain. 
In the K2264L structure, we observed intra-loop hydrophobic contacts between Leu2264 
and Val2262 (Figure 2.4H), rather than contacts with SET-I that we had designed to stabilize the 
loop. The new intra-loop interaction between Leu2264 and Val2262 distorts the loop and 
disrupts the interaction between the autoinhibitory loop and SET-I subdomain. These results 
suggest that the ~50% reduced activity of the K2264L mutant is caused by perturbations to the 
structure of the autoinhibitory loop. Interestingly, we observed very high B factors for the 
K2264L autoinhibitory loop (Table 2.1), indicating that despite new contacts between Leu2264 
and Val2262 the loop has enhanced dynamics relative to WT ASH1L. These observations further 
support the conclusion that disruption of the structure and dynamic properties of the 
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autoinhibitory loop is detrimental to enzyme activity.  
The crystal structure of the hyperactive Q2265A mutant shows only minor differences in 
the conformation of the autoinhibitory loop as compared to wild-type protein (Figure 2.4I), in 
agreement with the minimal effect of the Q2265A mutation on the NMR spectrum. In addition, 
crystallographic B factors for the Q2265A autoinhibitory loop are comparable to those of wild-
type (Table 2.1). Although possible, we did not observe evidence that different crystal packing 
of the Q2265A mutant artificially constrained the loop’s mobility. Therefore, our Q2265A 
structure suggests that enhanced activity of the Q2265A mutant may not be correlated with 
disordering of the autoinhibitory loop as previously suggested [127], but a co-crystal structure of 
ASH1L with nucleosome would be required to fully explain the effect of the Q2265A mutation. 
Finally, for all the mutants we did not find evidence that altered SAM binding contributed to 
changes in enzymatic activity, as there were no significant differences in SAM orientation or B 
factor relative to the structure’s average B factor (Table 2.1). 
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Table 2.1. Crystallographic data collection and refinement statistics for ASH1L WT and 
mutants.  
 ASH1L WT ASH1L 
S2259M 
ASH1L 
H2193F 
ASH1L 
Q2265A 
ASH1L 
K2264L 
PDB code 4YNM 4YNP 4YPE 4YPA 4YPU 
      
Data Collection  
Space group P3221 P3221 P3221 P1 P3221 
Cell dimensions  
 a, b, c (Å) 59.1, 59.1, 
231.0 
59.3, 59.3, 
233.9 
58.8, 58.8, 
232.2 
53.7, 61.8, 
73.2 
59.1, 59.1, 
226.0 
 α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120 91.6, 93.8, 
90.5 
90, 90, 120 
No. protein molecules 
in asymmetric unit 
2 2 2 4 2 
Resolution (Å) 50-2.20 
(2.24-2.20) 
50-2.90 
(2.95-2.90) 
50-2.20 
(2.24-2.20) 
50-2.30 
(2.34-2.30) 
50-2.60 
(2.64-2.60) 
Rmerge (%)
 9.5 (59.0) 8.8 (39.3) 7.3 (38.5) 6.0 (25.5) 8.8 (48.3) 
Rmeas (%) 10.1 (62.6) 9.4 (41.7) 8.0 (41.6) 8.6 (36.2) 9.3 (51.0) 
CC1/2 in outer shell 0.87 0.93 0.92 0.85 0.94 
I/σI 33.7 (3.5) 25.2 (4.4) 24.4 (4.1) 15.5 (2.8) 42.2 (6.4) 
Completeness (%) 99.9 (100.0) 96.1 (96.0) 86.1 (79.5) 96.0 (97.3) 99.4 (98.2) 
Redundancy 9.1 (9.1) 7.7 (7.4) 5.2 (5.7) 2.0 (2.0) 9.1 (9.0) 
  
Refinement  
Resolution (Å) 46.82-2.20 47.00-2.90 42.56-2.20 73.04-2.30 75.35-2.60 
No. of reflections 23,762 10,352 20,191 38,087 14,072 
No. of atoms 3497 3364 3572 7254 3373 
 Protein 3333 3304 3405 6920 3277 
 SAM 54 54 54 108 54 
 Zn
2+ 
6 6 6 12 6 
 Water 104 0 107 214 36 
Rwork/Rfree 24.2/27.8 26.2/31.9 21.7/26.3 24.9/30.3 23.8/30.5 
Average B-factor 42.4 54.7 32.2 38.0 53.1 
 Autoinhibitory loop 66.8 71.8 65.5 57.0 82.3 
 SAM 35.1 54.8 28.3 25.2 52.8 
RMSDs  
 Bond length (Å) 0.017 0.006 0.022 0.018 0.013 
 Bond angles (°) 1.769 0.973 1.940 1.645 1.479 
Ramachandran favored 
(%) 
93.3 90.0 92.3 91.3 89.7 
Ramachandran allowed 
(%) 
5.7 9.0 7.5 7.5 8.5 
Ramachandran outliers 
(%) 
1.0 1.0 0.2 1.2 1.8 
MolProbity clash score 11.86 4.74 10.7 16.6 7.41 
All diffraction data were obtained from a single crystal. Values in parentheses are for highest-resolution 
shell.
 
CC1/2 is the Pearson correlation coefficient of two half data sets as defined by Karplus and 
Diederichs.[174] 
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Structural insight into SET-I loop conformational dynamics  
We found that the Q2265A mutant crystallized in a different crystal form than the other 
ASH1L variants (P1 versus P3221, respectively) (Table 2.1). There are four ASH1L Q2265A 
molecules per asymmetric unit, and interestingly the Q2265A crystal traps two different 
conformations of the SET-I and autoinhibitory loops, with each conformation represented by a 
pair of ASH1L monomers (Figure 2.5A and B). The most interesting difference between the 
two conformations is the two orientations of His2193, with the histidine side chain forming a 
hydrogen bond either with the 3’ hydroxyl group of SAM or with the hydroxyl of Tyr2207 
(Figure 2.5A). Such conformational exchange is consistent with the WT structure, in which we 
observe poor electron density for His2193 (Figure 2.1C). Thus, the structure of the Q2265A 
mutant provides snapshots of two different conformations of the SET-I loop. We also observed 
significant differences in the autoinhibitory loop between the two different ASH1L 
conformations (Figure 2.5B), further emphasizing the conformational dynamics of this loop. 
We tested whether the Q2265A crystal structure could be used to corroborate the 
dynamics in ASH1L that we observed by NMR. We plotted pairwise distances between Cα 
positions for the two different ASH1L conformations observed in the crystal structure of this 
mutant. Compared to the rest of the core SET domain, we observed large structural differences 
for the SET-I and autoinhibitory loops (Figure 2.5C). The two molecules in the asymmetric unit 
of WT ASH1L also show structural differences for these loops, but the differences between 
molecules in the asymmetric unit are more significant and better resolved in the Q2265A mutant. 
Interestingly, residues which show these large structural differences are not observed in the 
NMR spectrum of the SET domain (both WT and Q2265A mutant). Therefore, intermediate 
dynamics that lead to broadening of NMR signals are consistent with conformational 
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heterogeneity observed in the crystal structure of Q2265A. 
 
Figure 2.5. Conformational dynamics observed in the crystal structure of Q2265A. (A) 
Superposition of SET-I loops for two different ASH1L molecules in asymmetric unit.  His2193 
can form a hydrogen bond either with the 3’ hydroxyl group of SAM or with the sidechain of 
Tyr2207. (B) Superposition of autoinhibitory loops for two different ASH1L molecules in 
asymmetric unit. (C) Pairwise distances between α carbons for the two ASH1L conformations 
observed in the Q2265A crystal. SET-I and autoinhibitory loop regions are highlighted by grey 
fields, residues unassigned in NMR spectra are shown in red. 
 
Conformational exchange in the SET-I loop contributes to ASH1L activity  
Analysis of the crystal structure of WT and Q2265A ASH1L indicated that the SET-I 
loop samples different conformations. We expected that such conformational heterogeneity 
might be partially regulated by His2193 which we found in two different conformations (Figure 
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2.5A). To probe the role of H2193 we introduced an H2193F mutation to disrupt its potential to 
form hydrogen bonds. We found that the H2193F mutation decreases activity of SET-BAH by 
more than 80% (Figure 2.6A). NMR studies of ASH1L H2193F showed that the mutation 
causes widespread chemical shift perturbations extending in a shell surrounding the dynamic 
SET-I and autoinhibitory loops (Figure 2.6B). We determined the crystal structure of H2193F 
and found a large ~8 Å conformational shift in the SET-I loop, with minimal perturbations to 
other regions when compared to wild-type protein (Figure 2.6C). Phe2193 in this mutant forms 
new hydrophobic contacts with Tyr2255, Val2262, and Ile2279 (Figure 2.6C and D). 
Interestingly, despite the significantly different conformation of the SET-I loop, the 
conformation of the autoinhibitory loop is unaffected. Altogether, these results demonstrate that 
conformational dynamics of the SET-I subdomain also play a significant role in modulating 
catalytic activity of the ASH1L SET domain. Furthermore, the dynamics of the SET-I 
subdomain occur in concert with those of the autoinhibitory loop (Figure 2.6E) to affect 
regulation of enzymatic activity. 
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Figure 2.6. Structural perturbation in SET-I loop induced by the H2193F mutation. (A) 
Enzymatic activity of wild-type and H2193F ASH1L with 0.25 μM ASH1L and 1.7 μM chicken 
mono/di nucleosome substrate. (B) Chemical shift perturbations in TROSY spectra induced by 
H2193F, color coding as in Figure 4. (C) Superposition of the SET-I loops of H2193F (blue) and 
wild-type (grey). Residues involved in hydrophobic contacts with Phe2193 are shown and 
labeled. (D) The SET-I loop of H2193F mutant with mFo-DFc omit map contoured at 2.5σ. 
Residues forming hydrophobic contacts to Phe2193 are shown. (E) Superposition of crystal 
structures of WT ASH1L and four mutants. 
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Discussion 
SET domain-containing KMTases are an important class of enzymes that constitute 
attractive targets for new therapeutics [175], but many structural aspects of SET domains remain 
poorly understood. The autoinhibitory loop is a striking feature observed in the crystal structure 
of the ASH1L SET domain. However, whether the loop functions as a simple swinging gate to 
allow access to the active site, or instead plays a more active role in substrate binding, is 
unknown. In this study we provide experimental evidence supporting the latter model. First, 
point mutations that destabilize the autoinhibitory loop did not increase enzymatic activity, as 
would be expected if the loop simply blocks access for substrate binding. Second, point 
mutations in the autoinhibitory loop that cause larger structural perturbations in the SET domain 
as judged from NMR and crystallography caused a substantial loss of enzyme activity, while 
point mutations that had smaller effects on the structure caused no change or even resulted in an 
increase in enzymatic activity compared to wild-type ASH1L. This suggests that the proper 
structure of the autoinhibitory loop is necessary for substrate binding, and the loop itself 
represents an important regulatory feature of the SET domain.  
We discovered that in addition to the autoinhibitory loop, the SET-I loop plays an 
important role in ASH1L SET domain function. The dynamics of this conformationally 
heterogeneous loop are partly regulated by His2193, a residue in the SET-I loop that adapts two 
different conformations and mutation of which significantly impairs enzymatic activity. In other 
SET domain-containing proteins, the SET-I region is poorly conserved and forms key contacts 
with histone substrates [132,176–179], indicating that it likely functions in determining substrate 
specificity among different KMTases [180]. In the structure of the related Pr-Set7 KMTase 
bound to a histone H4 fragment, the SET-I loop forms extensive contacts with the H4 peptide 
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[132,176]. Our results indicate that SET-I is also important to the enzymatic activity of ASH1L, 
likely through forming analogous contacts with histone H3 residues. 
Crystallographic and NMR studies of the SET domain and multiple mutants showed that 
the autoinhibitory loop and SET-I loop experience conformational dynamics occurring on the 
microsecond-millisecond timescale. Importantly, this conformational heterogeneity experienced 
in the absence of bound substrate does not appear to include an open, substrate-accessible form 
of the SET domain. The fully open conformation of ASH1L would require a much larger 
conformational change than any we observed and most likely such conformation can be achieved 
in the presence of nucleosome. However, the conformational dynamics we observed probably 
facilitate the major structural change leading to opening of the substrate binding site. Indeed, 
dynamic loops important for nucleosome binding have been characterized in a variety of 
chromatin-interacting domains, such as the Sir3 BAH domain [181], the PCAF/GCN5 histone 
acetyltransferase [182], and bromodomains [183]. For example, multiple crystal structures of the 
Sir3 BAH domain showed that residues in two flexible loops are completely disordered in the 
free BAH domain structure [184,185], but these residues become ordered or partially ordered 
upon binding to nucleosome [181]. 
We also found that in vitro ASH1L is much more active on native nucleosomes than 
recombinant nucleosomes. Furthermore, ASH1L constructs including chromatin binding 
domains have significantly enhanced activity compared to the isolated SET domain. Together 
these findings suggest a model whereby chromatin-binding domains of ASH1L recognize 
posttranslational modifications on native nucleosomes and facilitate catalytic activity of the SET 
domain via substrate recruitment. Interestingly, the results of Eram et al. showing enhanced 
activity of the isolated ASH1L SET domain on native nucleosomes[160] suggest that the SET 
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domain itself may also have increased affinity for native nucleosomes. In previous studies, 
ASH1L has been reported to methylate both H3K4 and H3K36 [44,93,127,157–160]. While the 
precise targets of ASH1L in vivo are still under investigation, such promiscuity suggests that 
ASH1L specificity depends on the nature of the substrate, similar to the NSD family [79]. The 
number of methyl groups transferred by ASH1L is an additional unanswered question with 
important implications for control of gene expression. In an in vitro enzyme assay, ASH1L can 
mono- and dimethylate, but not trimethylate, H3K36 [160]. On the other hand, there is in vivo 
evidence in mouse that ASH1L may trimethylate H3K36 [93]. The autoinhibitory loop may 
function to regulate the number of methyl groups transferred, because the Q2265A mutation 
leads to H3K36me3 in addition to the original H3K36me2 product [127].  
In summary, we discovered concerted dynamics in two loops of the ASH1L SET domain 
and showed that these loops regulate ASH1L enzymatic activity. Conformational dynamics in 
the substrate binding region of ASH1L may create transient pockets into which small molecule 
ligands could bind. Thus, it may be feasible to exploit the conformational dynamics to design 
small molecule inhibitors of ASH1L.  
56 
 
Chapter 3. Development of small molecule inhibitors for the ASH1L histone methyltransferase 
 
Abstract 
 
 The ASH1L histone methyltransferase is overexpressed in multiple cancers and activates 
oncogenic HOX genes. Small molecule inhibitors of ASH1L would be excellent tools to further 
investigate the role of ASH1L in cancer and could be the precursors of novel therapeutics; 
however, ASH1L inhibitors have not been reported to date. The ASH1L SET domain contains a 
conformationally heterogeneous autoinhibitory loop that blocks access of histone substrate to the 
enzyme active site. We used fragment based screening to identify a fragment-like ligand that 
binds to the autoinhibitory loop region of ASH1L. Structure-guided optimization of the ligand 
resulted in over 1000-fold improvement in binding affinity compared to the fragment screening 
hit. The optimized compound SK-1 inhibits ASH1L enzymatic activity with an IC50 value of 4.6 
± 1.9 μM and binds to ASH1L with Kd of 1.7 μM. Crystallographic and NMR studies indicate 
that SK-1 and related compounds inhibit ASH1L activity by stabilizing the autoinhibited 
conformation of the SET domain. This study demonstrates that fragment screening coupled with 
structure-based drug design can be used to develop potent and specific inhibitors for challenging 
epigenetic targets.
                                                          
Rogawski DS, et al. ASH1L inhibitors block leukemogenesis through downregulation of Hox 
gene expression. Manuscript in preparation. 
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Introduction 
 
 ASH1L is a histone 3, lysine 36 (H3K36)-specific methyltransferase (KMTase) that is an 
emerging cancer drug target due to its overexpression in multiple cancers and role in activating 
oncogene expression. Twenty-seven percent of aggressive, basal-like breast cancers have high-
level copy number amplifications of the ASH1L gene [95]. In addition, high levels of ASH1L 
mRNA are associated with shorter survival in breast cancer patients [95]. In thyroid cancer, 
ASH1L is overexpressed in tumor-specific truncated forms and is downregulated by a tumor 
suppressor microRNA [94]. ASH1L activates genes in the HOX-A, -B, -C, and -D clusters 
[15,93,96,159], which are overexpressed in multiple cancers and correlated with metastasis and 
aggressive disease [89]. Notably, ASH1L activates HOXA9 and its collaborator MEIS1 [15], 
which are oncogenes in leukemia [168]. 
Small molecule inhibitors of ASH1L KMTase activity would be invaluable tools to 
investigate the role of ASH1L in cancer, but such compounds have not been reported to date. To 
develop potent and specific inhibitors of ASH1L, we recalled our and others’ biophysical studies 
of the catalytic SET domain of ASH1L, which showed that an autoinhibitory loop blocks access 
of histone substrate to the active site [127,134]. Interestingly, the autoinhibitory loop and 
surrounding region experience conformational heterogeneity in the absence of nucleosome 
substrate [134]. We hypothesized that conformational dynamics in the autoinhibitory loop region 
could create transient pockets into which small molecule ligands could bind. Moreover, these 
ligands could possibly function as allosteric inhibitors by preferentially interacting with and 
stabilizing the autoinhibited form of ASH1L SET. Because the autoinhibitory loop is poorly 
conserved in primary sequence and structure, inhibitors that bind to the ASH1L autoinhibitory 
loop region would be predicted to have excellent selectivity over related KMTases. 
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As there are no known small molecule ligands of the ASH1L autoinhibitory loop region, 
we chose to take a fragment-based drug discovery (FBDD) approach [186], which would allow 
us to probe ASH1L SET for potential small molecule binding sites and then construct new 
ligands specific to ASH1L. FBDD is further advantageous because it requires relatively small 
compound libraries to sample chemical space, and often results in improved physicochemical 
and pharmacokinetic properties of lead compounds [187]. Our FBDD strategy identified a ligand 
that binds to the ASH1L autoinhibitory loop region. We then used information from NMR and 
crystallographic studies to optimize the fragment-like ligand into a potent and specific ASH1L 
inhibitor. This study identifies the first ASH1L inhibitor and provides the first example of 
successfully applying FBDD to KMTases. 
Results 
 
FBDD identifies a novel ligand of ASH1L SET domain 
 
 We conducted fragment screening of the ASH1L SET domain using 
15
N-
1
H TROSY 
NMR, a highly sensitive method for detecting ligand binding to any site on ASH1L. We 
screened 1500 fragment-like compounds (MW<300) in the presence of twofold excess SAM 
cofactor over ASH1L to find ligands that do not compete with SAM. This screen produced two 
hits that caused perturbations to the same TROSY peaks, suggesting the two ligands bind to the 
same site. The low hit rate indicates that ASH1L SET does not generally bind to fragment-like 
compounds, but only to a privileged class of compounds that form specific interactions with the 
SET domain. The stronger of the two hits, thioamide 1, causes chemical shift perturbations or 
broadening of multiple TROSY peaks (Figure 3.1A). We determined from NMR titrations that 1 
binds to ASH1L SET with affinity weaker than 1 mM (data not shown).  
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To identify the binding site of 1, we took advantage of our previously reported 
assignment of the ASH1L TROSY spectrum [134]. Notably, we do not observe TROSY peaks 
corresponding to the autoinhibitory loop region of ASH1L due to conformational heterogeneity 
and peak broadening. We mapped chemical shift perturbations caused by binding of 1 onto the 
ASH1L SET crystal structure (Figure 3.1B). We found that the perturbations mapped to a shell 
surrounding the unassigned autoinhibitory loop region. This result suggests that 1 binds to the 
conformationally dynamic autoinhibitory loop region, causing observable perturbations to 
residues surrounding this region. To confirm that 1 binds to the autoinhibitory loop region, we 
mutated Ser2259 in the autoinhibitory loop to methionine (Figure 3.1C). Introduction of the 
bulky methionine side chain in the autoinhibitory loop abrogated binding of 1 while causing 
minor changes to the overall TROSY spectrum (Figure 3.1D), indicating that 1 binds to the 
autoinhibitory loop region of ASH1L.  
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Figure 3.1. Identification of a fragment-like ligand of the ASH1L SET domain. (A) A region of 
the 
15
N-
1H TROSY spectrum of ASH1L SET (100 μM) with no compound (black) and 1 mM 1 
(red). Structure of 1 shown at left. (B) Perturbations to the TROSY spectrum induced by binding 
of 1 mapped onto the SET domain crystal structure (PDB code 4YNM). (C) Location of Ser2259 
in the autoinhibitory loop (cyan). SET-I subdomain colored light purple, core SET subdomain 
colored light blue, and post-SET subdomain colored pale yellow. (D) S2259M mutation prevents 
binding of 1 to ASH1L SET, as shown by lack of chemical shift perturbations in the presence of 
1 mM 1. 
 
Medicinal chemistry optimization of fragment screening hit 1 
 
 To improve the potency of 1, we undertook a systematic medicinal chemistry campaign, 
synthesizing over 130 compounds total (Appendix). To compare weak compounds with affinities 
in the high micromolar to millimolar range, we developed an NMR-based estimation of affinity 
called 3 Peak Affinity (3PA). The 3PA is based on the premise that for NMR peaks showing a 
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fast exchange binding mode and at a compound concentration within 2-3-fold of the Kd, the 
relative affinity of different compounds correlates with the size of the induced chemical shift 
perturbations. The 3PA is calculated by taking the average of the chemical shift perturbations in 
hertz at 3 TROSY peaks (G2163, K2228, and I2278) in the presence of 500 μM compound (see 
Methods for details). More potent compounds induce larger chemical shift perturbations and 
receive a higher 3PA score.  
We began optimization of 1 by exploring changes to the pyrrole group. Substitution of 
the pyrrole with phenyl in 1a improved the 3PA to 25.38 Hz compared to 7.78 Hz for 1 (Table 
3.1). A hydroxyl derivative 1b had improved solubility and potency with a 3PA of 29.76. 
Subsequent methylation of the hydroxyphenyl at the R1 and R2 positions further improved 
binding in 1c and 1d, with 3PA values of 48.71 and 36.31, respectively. We were able to analyze 
binding of 1c to ASH1L by isothermal titration calorimetry (ITC) and found a Kd value of 135 
μM (data not shown). In the context of the hydroxyphenyl (1b) we performed nitrogen scanning 
in the thioamide-conjugated ring (Table 3.1). We found that pyridine derivatives 1e and 1f 
showed dramatically reduced binding compared to 1b, but 1g had increased potency with a 3PA 
of 40.45. We next performed methylation of the thioamide-conjugated ring at the R4 and R5 
positions in 1h and 1i, but found that both compounds had decreased potency by NMR compared 
to 1b.  
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Table 3.1. Medicinal chemistry optimization of fragment screening hit 1. 
 
The SAR thus far indicated that substitutions to the thioamide-conjugated ring were in 
general not tolerated (Table 3.1 and Appendix). In contrast, expansion of the pyrrole to indole 2 
dramatically improved affinity as evidenced by a slow exchange binding mode observed by 
NMR. For example, as 2 is titrated into ASH1L SET, we observe two TROSY peaks for G2163, 
with the relative peak heights changing with increasing amounts of 2 (Figure 3.2A). To test 
whether the more potent 2 could inhibit ASH1L enzymatic activity, we used an in vitro enzyme 
assay with nucleosomes as substrate [134]. Consistent with our hypothesis that ligands of the 
autoinhibitory loop region should block enzymatic activity, we found that 2 inhibits ASH1L with 
IC50 value of 76 μM (Figure 3.2A). An isomer of 2 with indole attached at the 3 position to the 
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thioamide-conjugated ring (3) had a similar IC50 of 100 μM (Figure 3.2B and C) and proved a 
more tractable scaffold for further synthesis. 
 We next focused our medicinal chemistry efforts on optimization of the indole of 3. 
Synthesis of over 50 compounds with this scaffold indicated that substitutions at the 1 and 6 
positions of the indole generally improved potency while substitutions at other positions were 
not tolerated (Appendix). Substitution of the indole at position 1 with hydroxyethyl to yield 4 
improved potency fivefold to an IC50 of 22 μM. In addition, substitution at position 6 with 
methylamine 5 improved potency threefold to an IC50 of 36 μM. We found that combining these 
two substituents in 6 had an additive effect, with IC50 of 13 μM (Figure 3.2C). The Kd of 6 as 
measured by ITC is 4.6 μM (Figure 3.2D). 
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Figure 3.2. Biochemical and structural characterization of ASH1L inhibitors. (A) Compound 2 
binds to ASH1L with slow exchange kinetics on the NMR timescale. (B) Comparison of ASH1L 
inhibitor potency in in vitro KMTase assay. (C) Substitutions at the 1 and 6 positions of the 
indole have an additive effect on inhibitor potency. (D) Binding of 6 to ASH1L by ITC. (E) 
Crystal structure of 6 (magenta) bound to ASH1L. Inhibitor binding causes a conformational 
change in the autoinhibitory and SET-I loops. (F) Crystal structure of 6 (magenta) bound to 
ASH1L with 2Fo-Fc map contoured at 1.0σ. Autoinhibitory loop shown in yellow, SET-I loop in 
blue, core SET in cyan, post-SET in orange, and SAM cofactor in green. (G) Interactions made 
by thioamide group in structure of 6 bound to ASH1L. (H) Interactions made by hydroxyethyl 
and methylamine groups of 6.  
65 
 
Crystal structure of 6 in complex with ASH1L SET shows details of protein-ligand interaction 
and stabilization of autoinhibitory loop region   
 
To further characterize binding of bi-substituted 6 and obtain structural information for 
inhibitor design, we crystallized the ASH1L SET domain in complex with 6. Crystals of the 
wild-type SET domain grown in the presence of inhibitors consistently diffract to low resolution 
(~3 Å), precluding detailed structural analysis. However, we found that crystals of 6 in complex 
with Q2265A mutant ASH1L diffracted to 1.7 Å and showed excellent electron density for the 
inhibitor. Consistent with our previous NMR mapping and mutagenesis studies, 6 binds to the 
autoinhibitory loop region of ASH1L, with the autoinhibitory loop wrapping around 6 on three 
sides (Figures 3.2E and F). The loop undergoes a conformational change in which the 
sidechains of Ser2259 and His2193 rotate away from the binding site to accommodate the 
inhibitor, while Val2262 and Asn2261 adjust to make van der Waals contacts with the phenyl 
and indole of 6, respectively (Figure 3.2E). Binding of 6 also induces formation of a β-turn at 
the C-terminus of the post-SET subdomain, and Ile2279 and Gly2280 within this turn make 
hydrophobic contacts to the inhibitor (Figure 3.2F). The thioamide group of 6 binds deep inside 
the protein, with the thioamide forming a sulfur-oxygen chalcogen bond [188] to the backbone 
carbonyl of His2193 (Figure 3.2G). The thioamide nitrogen forms hydrogen bonds with the 
backbone carbonyls of Cys2195 and Phe2260. Closer to the surface of the protein, the 
hydroxyethyl substituent on the indole forms a hydrogen bond with the backbone carbonyl of 
Ile2279, while the methylamine forms hydrogen bonds to the Asn2256 sidechain and the 
Gly2280 backbone carbonyl (Figure 3.2H). 
 Compared to the crystal structure of ASH1L without ligand, the resolution of the crystal 
structure of ASH1L bound to 6 is significantly higher (1.7 versus 2.3 Å) and the average protein 
B factor is substantially lower (16.6 ± 10.1 Å
2 
versus 38.3 ± 16.0 Å
2
, mean and standard 
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deviation) (Table 3.2), suggesting that 6 stabilizes dynamics of the ASH1L SET domain. To 
determine if the autoinhibitory loop region is particularly stabilized by inhibitor binding relative 
to the rest of the SET domain, we converted raw B factors to normalized B factors, thereby 
correcting for the large difference in average B factor between the free SET domain and SET 
domain/inhibitor complex (see Methods). We found that normalized B factors for the 
autoinhibitory loop and the SET-I loop were significantly lower in the crystal structure of 
ASH1L in complex with 6 compared to the structure of ASH1L alone (Figures 3.3A and B). In 
addition, by NMR we found that binding of 6 perturbs the majority of TROSY peaks for ASH1L 
and causes appearance of several new peaks (Figure 3.3C). Further inspection of ITC 
parameters revealed a thermodynamic signature of binding for 6 and related compounds, 
characterized by a favorable change in enthalpy (ΔH=-13.0 kcal/mol) and an unfavorable 
entropic component (-T∆S=5.7 kcal/mol) (Figure 3.3D) likely due to conformational changes of 
the SET domain upon ligand binding [189]. Together, these results suggest that 6 and related 
compounds inhibit ASH1L activity by stabilizing the autoinhibited conformation of the SET 
domain. 
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Table 3.2. Crystallographic data collection and refinement statistics for crystals of ASH1L 
Q2265A in complex with inhibitors.
a
  
 No compound 6 9 SK-1 
Data Collection 
Space group P1 P1 P1 P1 
Cell dimensions 
 a, b, c (Å) 53.7, 61.8, 73.2 54.1, 62.3, 73.0 53.9, 62.1, 72.9 53.1, 61.3, 71.8 
 α, β, γ (°) 91.6, 93.8, 90.5 87.8, 85.6, 90.0 92.0, 94.4, 90.0 88.1, 85.7, 89.6 
No. protein 
molecules in 
asymmetric unit 
4 4 4 4 
Resolution (Å) 50−2.30 (2.34-
2.30) 
50-1.70 (1.73-
1.70) 
50-1.77 (1.80-
1.77) 
50-1.65 (1.68-
1.65) 
Rmerge (%)
 6.0 (25.5) 9.6 (59.1) 11.9 (63.4) 8.2 (57.9) 
Rmeas (%) 8.6 (36.2) 11.1 (69.0) 13.8 (74.5) 9.3 (66.3) 
CC1/2
b
 in outer shell 0.85 0.73 0.68 0.79 
I/σI 15.5 (2.8) 14.4 (2.1) 15.9 (2.1) 26.0 (2.1) 
Completeness (%) 96.0 (97.3) 96.5 (94.1) 97.0 (95.2) 97.1 (95.2) 
Redundancy 2.0 (2.0) 3.9 (3.7) 3.9 (3.7) 4.2 (4.2) 
 
Refinement 
Resolution (Å) 73.04−2.30 40.86-1.69 36.05-1.78 40.13-1.63 
No. of reflections 38087 96238 83517 103276 
No. of atoms 7254 8349 8226 8098 
 Protein 6920 7027 7008 7108 
 SAM 108 108 108 108 
 Zn
2+ 
12 12 12 12 
 Ligand -- 92 96 100 
 Water 214 1110 1002 770 
Rwork/Rfree 24.9/30.3 19.0/24.1 22.2/28.5 17.8/22.1 
Average B-factor 38.0 18.1 22.6 28.4 
 Protein 38.3 16.6 21.4 27.8 
 SAM 25.2 8.9 10.4 17.6 
 Zn
2+
 34.0 12.6 19.3 25.0 
 Ligand -- 15.5 20.2 25.0 
 Water 36.2 29.0 32.3 37.1 
RMSDs 
 Bond length (Å) 0.018 0.030 0.023 0.026 
 Bond angles (°) 1.645 2.228 2.143 2.411 
Ramachandran 
favored (%) 
91.3 93.9 92.1 95.5 
Ramachandran 
allowed (%) 
7.5 5.1 6.9 3.3 
Ramachandran 
outliers (%) 
1.2 1.0 1.0 1.2 
MolProbity clash 
score 
16.6 10.96 14.8 11.32 
a
All diffraction data were obtained from a single crystal. Values in parentheses are for the 
highest-resolution shell. 
b
CC1/2 is the Pearson correlation coefficient of two half-data sets as 
defined by Karplus and Diederichs.[174] 
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Figure 3.3. Compound 6 stabilizes autoinhibited conformation of ASH1L SET domain. (A) 
Normalized B factors for ASH1L without ligand and ASH1L bound to 6. (B) Box and whiskers 
plot of normalized B factors for the autoinhibitory and SET-I loops of ASH1L without ligand 
and ASH1L bound to 6. Whiskers show min to max. *P<0.0001, t test. (C) 
15
N-
1
H TROSY 
spectra of ASH1L without ligand (black) and ASH1L saturated with 6 (red). Arrowheads mark 
peaks in the red spectrum lacking counterparts in the black spectrum. (D) Thermodynamic 
parameters of binding of 6 to ASH1L SET, determined from ITC. 
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Structure-based design of SK-1 
Based on the high resolution structure of ASH1L with 6, we designed another series of 
compounds with substitutions at positions 1 and 6 of the indole. First we tested whether 
hydrogen bonding to the protein could be optimized by modifying the methylamine at position 6 
to amine 7 (Table 3.3). This modification led to a small decrease in potency in the enzyme assay 
but a small improvement in Kd measured by ITC from 4.6 μM in 6 to 4.0 μM in 7. Next, in the 
structure with 6 we observed several backbone carbonyls in the vicinity of the hydroxyethyl 
substituent. Although the carbonyl groups are not oriented optimally for formation of hydrogen 
bonds with the inhibitor, we hypothesized that fluorinated substituents at position 1 of the indole 
might engage in orthogonal C–F···C═O interactions with the carbonyls [190]. Therefore, in the 
context of amine at position 6, we synthesized trifluorobutyl 8 and difluoropropyl 9, which had 
Kd values of 3.4 and 2.0 μM, respectively (Table 3.3 and Figure 3.4A, ITC data not shown). 
Compound 9 also has an enzyme assay IC50 value of 3.6±0.1 μM, making it the most potent 
ASH1L inhibitor thus far. A crystal structure of 9 in complex with ASH1L revealed two different 
conformations of the difluoropropyl group in different ASH1L monomers of the asymmetric 
unit, with the fluorines capable of interacting either with the backbone carbonyl of Lys2264 or 
that of Gly2280 (Figure 3.4B).  
To enhance potency by forming two fluorine-backbone interactions simultaneously, we 
synthesized a branched fluoropropyl derivative SK-1 (Figure 3.4A). SK-1 inhibited ASH1L 
enzymatic activity with an IC50 of 4.6±1.9 μM and bound to ASH1L with a Kd of 1.7 μM 
(Figure 3.4C), values similar to 8. The ITC experiment showed thermodynamic parameters 
similar to 6, with a favorable change in enthalpy (ΔH=-17.2 kcal/mol) and an unfavorable 
entropic component (-T∆S=9.3 kcal/mol) (Figure 3.4C), underscoring a binding event driven by 
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enthalpy, with formation of hydrogen and chalcogen bonds and van der Waals interactions 
within the binding pocket. Interestingly, a co-crystal structure of SK-1 showed that the branched 
fluoropropyl substituent does not interact strongly with the backbone carbonyls of Lys2264 or 
Gly2280. Instead, the branched substituent fills the concave surface formed by residues Ile2278, 
Ile2279, Gly2280, and Gly2281 as they make a β-turn (Figure 3.4D). 
 To evaluate selectivity of SK-1 for ASH1L, we tested the effect of SK-1 on the 
enzymatic activity of related SET domains including NSD1-3, SETD2, and EHMT2. The most 
closely related SET domain, NSD1, shares 46% sequence identity to ASH1L SET. We found 
that low micromolar concentrations of SK-1 that inhibit ASH1L by 50% or more have minimal 
or no effect on related SET domains, demonstrating excellent selectivity of SK-1 for ASH1L 
(Figure 3.4E). 
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Table 3.3. Medicinal chemistry optimization of indole scaffold. 
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Figure 3.4. Development of SK-1. (A) Chemical structures of 9 and SK-1. (B) Crystal structure 
of ASH1L bound to 9. Two different molecules of ASH1L SET in the asymmetric unit bound to 
9 are shown in cyan and magenta. (C) Binding of SK-1 to ASH1L SET by ITC. Thermodynamic 
parameters of binding are listed and graphed. (D) Crystal structure of ASH1L bound to SK-1. 
(E) Selectivity testing of SK-1 across a panel of related KMTases. 
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Optimizing substituents at position 6 of indole and combining with substituents at position 1 
In the context of the trifluorobutyl group at position 1, we attempted to optimize the 
substituent at position 6 by introducing more bulky substituents as well as a different hydrogen 
bond donor. The resulting imidazole with amine linker 10 and hydroxymethyl 11 compounds 
both had Kd values of 2.1 μM (Table 3.3, ITC data not shown), approaching a 2-fold 
improvement over the amine (compound 8). At this point the SAR suggested that the best indole 
substituents were the difluoropropyol or branched monofluoropropyl at position 1 and imidazole 
with amine linker or hydroxymethyl at position 6. We combined branched fluoropropyl and 
hydroxymethyl substituents in 12, which has a Kd of 1.1 μM (Figure 3.5A, ITC data not shown). 
We combined difluoropropyl and hydroxymethyl substituents in 13, which has a Kd of 0.9 μM 
(Figure 3.5A and B). These results confirm that combining substituents at the 1 and 6 positions 
has an additive effect on binding affinity. 
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Figure 3.5. Combination of optimized substituents at 1 and 6 positions. (A) Chemical structures 
of 12 and 13, with Kd values listed. (B) Binding of 13 to ASH1L by ITC. Thermodynamic 
parameters listed. 
 
Sulfur-oxygen chalcogen bonding in ASH1L-inhibitor complexes 
In all the co-crystal structures with ASH1L and inhibitors, we observed a sulfur-oxygen 
chalcogen bond between the thioamide sulfur of the inhibitor and the carbonyl oxygen of 
His2193. For example, in the SK-1 co-crystal structure the thioamide sulfur is positioned 3.0 Å 
from the His2193 carbonyl oxygen (Figure 3.6). Interestingly, many methyltransferases 
including SET domains use sulfur-oxygen chalcogen bonding to mediate recognition of the SAM 
cofactor, which contains a sulfonium cation [188]. Although chalcogen bonding to SAM is not 
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observed in structures of ASH1L SET in the absence of inhibitor (≤ 3.2 Å required between 
sulfonium and an oxygen), the backbone carbonyl oxygen of His2193 is intriguingly close (3.3-
3.9 Å) to the SAM sulfonium [134]. Given that His2193 is located in a conformationally 
heterogeneous region of ASH1L SET [134], it remained possible that this residue engages in 
S···O chalcogen bonding transiently in solution, but the bond was not captured in the static 
crystal structure. Remarkably, the ASH1L inhibitors trigger a protein conformational change 
resulting in the His2193 carbonyl forming a chalcogen bond with SAM. For example, in the SK-
1 co-crystal structure, the His2193 carbonyl oxygen is 3.2 Å from the sulfonium of SAM 
(Figure 3.6). Thus, binding of SK-1 and related inhibitors creates a chalcogen bonding network 
involving the inhibitor, His2193, and SAM (Figure 3.6). By stabilizing the conformationally 
dynamic region of ASH1L, the inhibitors reveal a propensity for S···O chalcogen bonding 
between His2193 and SAM. Further crystallographic, NMR, and quantum mechanical studies 
may help determine if this bond plays a role in enzymatic activity. 
 
Figure 3.6. Chalcogen bonds induced by binding of SK-1 to ASH1L SET. SK-1 forms a 
chalcogen bond with the H2193 carbonyl oxygen, which in turn forms a chalcogen bond with the 
sulfonium of SAM. ASH1L Q2265A structure shown in grey, SK-1-bound ASH1L Q2265A 
structure shown in cyan. 
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Discussion 
 An autoinhibitory loop that blocks access of histone substrate to the active site is a unique 
feature of H3K36-specific SET domains. Although this loop was an interesting structural 
element, it was previously unclear how to exploit this loop for inhibitor development because 
there were no natural or synthetic small molecule ligands that bound to the loop region. It 
seemed likely that new chemical scaffolds would be required to target this site, perhaps which 
did not exist in HTS libraries. Here we have shown that FBDD is an effective method for 
probing the druggability of the autoinhibitory loop region and identifying novel compounds that 
interact with the loop. Fragment screening identified a compound that formed multiple specific 
interactions with ASH1L SET but had weak affinity due to its small size. We optimized the 
compound to increase potency but maintained the original interactions made by the fragment. 
Expansion from pyrrole to bi-substituted indole resulted in a 1000-fold improvement in binding 
affinity. The advanced ASH1L inhibitors have a unique scaffold that has not been previously 
reported in the SciFinder database. NMR and crystallographic evidence suggests that these 
compounds inhibit ASH1L activity by stabilizing the autoinhibited conformation of the SET 
domain. This work represents the first ASH1L inhibitors reported to date. 
 SK-1 is a potent and selective ASH1L inhibitor developed through iterative structure-
based drug design. The thioamide group represents a unique chemical warhead, forming an 
elegant network of chalcogen and hydrogen bonds deep inside the protein. An additional 
chalcogen bond between His2193 and SAM induced by inhibitor binding may contribute to 
stabilization of the autoinhibitory loop region. The phenyl and indole rings of SK-1 form a 
scaffold that fills the pocket surrounded by the autoinhibitory loop. The branched fluoropropyl 
and amino substituents of the indole form additional contacts with the protein, together 
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contributing a greater than 20-fold increase in potency over the unsubstituted scaffold. Thus, SK-
1 represents an efficient ASH1L inhibitor with a well-characterized structure-activity 
relationship. This study provides some intriguing evidence for the role of sulfur-oxygen 
chalcogen bonding in protein and medicinal chemistry and suggests that this type of interaction 
might be considered when designing other small molecule inhibitors. We have also shown how 
fluorination can be used to improve inhibitor potency, either by orthogonal C–F···C═O 
interactions or van der Waals interactions. 
 In conclusion, in this work we used an innovative FBDD strategy to develop the first 
small molecule inhibitors of ASH1L. Structure-based medicinal chemistry optimization 
improved inhibitor potency greater than 1000-fold compared to the original fragment screening 
hit. These compounds are specific to ASH1L, are predicted to be cell-penetrant, and will be 
valuable tools for investigating the function of ASH1L in cancer and other diseases. 
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Chapter 4. Genetic and pharmacologic approaches identify novel functions of ASH1L in breast 
cancer and leukemia

 
 
Abstract 
 
 ASH1L is an epigenetic regulator and histone lysine methyltransferase (KMTase) that is 
overexpressed in multiple forms of cancer and activates oncogenic HOX genes. To further 
investigate the role of ASH1L in cancer we performed genetic knockdown of the ASH1L gene 
and pharmacologic inhibition of ASH1L KMTase activity in cancer cells. We found that ASH1L 
is required for growth of breast cancer and leukemia cells, and that ASH1L activates HOXA 
genes and MEIS1 in leukemia. Moreover, targeted in-frame deletion of the ASH1L SET domain 
and pharmacologic inhibition of ASH1L KMTase activity revealed a key role for the ASH1L 
SET domain in leukemic transformation mediated by MLL-AF9 and CALM-AF10. The ASH1L 
inhibitor SK-1 selectively prevents growth and induces apoptosis and differentiation of MLL-
AF9-transformed mouse bone marrow cells. Conversely, SK-1 has no effect on differentiation of 
cells transformed by Hoxa9/Meis1. SK-1 also inhibits growth of MLL-rearranged human 
leukemia cell lines. Our results demonstrate cellular efficacy of ASH1L inhibitors and 
simultaneously uncover a new role for the ASH1L SET domain in acute leukemia. 
                                                          
Rogawski DS, et al. ASH1L inhibitors block leukemogenesis through downregulation of Hox 
gene expression. Manuscript in preparation. 
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Introduction 
 
 Epigenetic pathways are disrupted in cancer, causing aberrations in chromatin structure, 
gene expression, and genome integrity [8]. ASH1L is an epigenetic regulator and histone 3, 
lysine 36 (H3K36)-specific methyltransferase (KMTase) with an emerging role in cancer. 
ASH1L is overexpressed in a variety of solid tumors, including thyroid and breast cancer 
[94,161]. In thyroid cancer, ASH1L is overexpressed in tumor-specific truncated forms. The 
tumor suppressor microRNA miR-142-3p inhibits ASH1L protein expression by binding to the 
ASH1L 3’UTR, an effect correlated with inhibition of colony formation and slowing of thyroid 
cancer cell growth [94]. In addition, the ASH1L gene frequently undergoes copy number 
amplification in aggressive basal-like breast cancer, and high expression of ASH1L mRNA is 
associated with shorter survival of breast cancer patients [161]. Finally, in hepatocellular 
carcinoma (HCC), structural variations are found near the ASH1L gene, and knockdown of 
ASH1L in HCC cells slows proliferation [191].  
In multiple developmental and oncogenic contexts, ASH1L activates HOXA, -B, -C, and -
D genes and MEIS1[15,88,93,96]. ASH1L’s KMTase activity is required for at least some of its 
gene activating function, as deletion of the ASH1L SET domain in differentiating mouse 
embryonic stem cells leads to decreased expression of 152 genes, including members of the Hox 
and Wnt familes [93]. These findings are highly relevant because HOX genes are oncogenic 
drivers in many different blood and solid tumors [89]. For example, overexpression of HOXA9 is 
highly associated with a poor prognosis in acute myeloid leukemia (AML) [90], and HOXA9 
and its collaborator MEIS1 are required for survival of MLL-rearranged leukemia cells [91,92]. 
Interestingly, ASH1L deficiency causes a major reduction in long-term hematopoietic stem cells 
(HSCs) in mouse bone marrow, but surprisingly has very modest effects on peripheral blood 
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counts due to increased proliferation of progenitors downstream of HSCs [15]. ASH1L-deficient 
HSCs are also unable to reconstitute bone marrow output when transplanted into lethally 
irradiated mice [15]. These findings indicate that ASH1L maintains quiescence and self-renewal 
potential of long-term HSCs, but whether ASH1L regulates the stemness properties of leukemic 
stem cells is unknown. 
Despite the correlations between ASH1L and cancer, definitive evidence demonstrating 
the oncogenic potential of ASH1L has remained elusive. Here we undertook a combined genetic 
and pharmacologic approach to investigate ASH1L’s role in breast cancer and leukemia. We 
identified an important role for the ASH1L SET domain in activating HOX genes and 
maintaining leukemia in multiple cellular models. 
Results 
 
ASH1L regulates proliferation of breast cancer cells 
 
 Breast cancer cell lines mirror many of the molecular features found in patients and are 
useful model systems to investigate genes that contribute to oncogenesis [192]. Because ASH1L 
is frequently amplified in aggressive basal-like breast cancer, which includes the “triple-
negative” immunophenotype [161], we aimed to determine the extent to which ASH1L regulates 
proliferation of breast cancer cells. We selected two cell lines, MDA-MB-468, a triple negative 
cell line, and MCF-7, an estrogen receptor-positive line, and then used shRNA to knockdown 
ASH1L expression, resulting in a reduction in ASH1L mRNA of approximately 40-50% in both 
cell lines (Figure 4.1A and B). We found that MDA-MB-468 cells transduced with the ASH1L-
targeting shRNA grew more slowly over 12 days compared to cells transduced with a non-
targeting control shRNA (Figure 4.1C). In contrast, MCF-7 cells transduced with the ASH1L 
and non-targeting shRNAs grew at the same rate (Figure 4.1D). These results suggest that 
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ASH1L regulates growth of triple-negative breast cancer. Additional experiments are ongoing to 
determine genes regulated by ASH1L in breast cancer. 
 
Figure 4.1. Knockdown of ASH1L slows proliferation of MDA-MB-468 cells. (A) and (B) 
Relative expression of ASH1L in MDA-MB-468 (A) and MCF-7 (B) cells treated with non-
targeting shRNA (black) or ASH1L shRNA (red). Expression was normalized to HPRT1 and 
referenced to control shRNA-transduced cells. (C) and (D) Growth of MDA-MB-468 (C) and 
MCF-7 (D) cells treated with non-targeting shRNA (black) or ASH1L shRNA (red).  
 
ASH1L regulates HOX gene expression in human leukemia cells 
 
 ASH1L’s role in HOX gene activation in multiple developmental contexts [15,93] 
prompted us to determine whether ASH1L activates HOX genes in leukemia. We selected two 
human AML cell lines, THP-1 and KG1, for ASH1L knockdown experiments. THP-1 cells 
harbor the MLL-AF9 translocation, while KG1 cells lack MLL rearrangements but express high 
levels of HOXA genes. Transduction of cells with ASH1L shRNA led to a decrease in ASH1L 
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expression of 50-60% compared to cells transduced with a control shRNA (Figure 4.2A, B). In 
THP1 cells, we observed concomitant decreases in expression of HOXA5, HOXA9, HOXA10, 
and MEIS1 by 40-70%. In KG1 cells, ASH1L knockdown caused similar decreases in HOXA 
genes and MEIS1 of 20-60%. These data indicate that ASH1L regulates HOX and MEIS1 
expression in multiple AML cell lines.  
 
Figure 4.2. Relative expression of ASH1L and HOX genes in THP1 (A) and KG1 (B) cells 6 
days after transduction with an shRNA targeting ASH1L (red) or a nontargeting control shRNA 
(black). Data are representative of three independent experiments. Expression was normalized to 
GAPDH and referenced to control shRNA-transduced cells. 
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ASH1L regulates proliferation of CALM-AF10-transformed mouse bone marrow cells 
 
 ASH1L’s function in activating HOX genes suggested that ASH1L could regulate cell 
proliferation in acute leukemias that depend on HOX gene expression. Therefore, we chose to 
further study ASH1L’s role in leukemia by using mouse bone marrow cells transformed with the 
CALM-AF10 fusion gene (CALM-AF10 BMCs). CALM-AF10 is a rare but recurrent 
translocation observed in acute leukemia patients, and when expressed in mice the fusion gene 
induces a long-latency leukemia characterized by marked upregulation of Hoxa genes [193,194]. 
In collaboration with Andy Muntean’s laboratory (Department of Pathology, University of 
Michigan), we transduced CALM-AF10 BMCs with a doxycycline-inducible shRNA targeting 
Ash1l. After induction of the shRNA with doxycycline, Ash1l expression decreased 
approximately 50% compared to un-induced control cells (Figure 4.3A). To determine the extent 
to which Ash1l regulates growth of CALM-AF10 BMCs, we performed a competitive 
proliferation assay by culturing CALM-AF10 BMCs harboring the inducible Ash1l shRNA 
together with parental CALM-AF10 BMCs in the presence of doxycycline. We observed a 
steady decrease in DsRed+, Ash1l shRNA-expressing cells over the course of two weeks, with 
near complete elimination of DsRed+ cells at 17 days (Figure 4.3B). These results indicate that 
CALM-AF10 BMCs require Ash1l for proliferation. 
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Figure 4.3. Knockdown of Ash1l inhibits proliferation of CALM-AF10 BMCs. (A) qRT-PCR 
for Ash1l in CALM AF-10 BMCs expressing doxycycline-inducible shRNA targeting Ash1l. 
Expression was normalized to Gapdh and referenced to uninduced cells. (B) Percentage of 
DsRed+, Ash1l shRNA-expressing cells in 17-day growth competition assay with parental 
CALM-AF10 BMCs. 
 
The ASH1L SET domain is required for leukemic transformation 
 
 ASH1L is a large epigenetic regulator containing a catalytic SET domain as well as 
chromatin-interacting bromo, PHD, and BAH domains and an unannotated N-terminus. The 
function of different ASH1L regions and domains is poorly understood. Given that ASH1L is 
required for proliferation of CALM-AF10 BMCs, we aimed to determine the extent to which the 
ASH1L SET domain contributes to leukemogenesis. We obtained knock-in mice expressing 
mutant Ash1l containing a short in-frame deletion within the AWS-SET domain (ΔSET) (mice 
obtained from Ivan Maillard’s laboratory, Life Sciences Institute, University of Michigan, 
originally a kind gift from Gang Huang, Cincinnati Children’s Hospital, and Kenichi Nishioka, 
Saga University) [93]. We transduced ΔSET and wild-type BMCs with the CALM-AF10 and 
MLL-AF9 oncogenes and performed colony assays to determine whether the ASH1L SET 
domain is required for transformation by the oncogenes. After five rounds of plating, ΔSET 
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BMCs transduced with CALM-AF10 formed less than 20% the number of colonies that wild-
type BMCs formed (Figure 4.4A). In addition, after four rounds of plating, ΔSET BMCs 
transduced with MLL-AF9 formed no visible colonies compared to robust colony formation by 
wild-type BMCs transduced with MLL-AF9 (Figure 4.4A). Microscopy revealed dense and 
compact colonies for wild-type cells transformed by MLL-AF9, but only diffuse small clusters of 
ΔSET cells, indicating a failure of transformation in the ΔSET cells (Figure 4.4B). Wright-
Giemsa staining showed substantial morphological differences between ΔSET and wild-type 
BMCs transduced with the CALM-AF10 and MLL-AF9 oncogenes at the last round of the 
colony assay (Figure 4.4C). The wild-type cells had a blast-like morphology, but the ΔSET cells 
had increased cell size, lower nuclear-to-cytoplasmic ratio, and highly vacuolated cytoplasm, 
indicative of differentiation to a macrophage-like phenotype. These results indicate that the 
ASH1L SET domain is required for transformation by multiple leukemic oncogenes. 
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Figure 4.4. Colony formation by ΔSET and wild-type mouse BMCs. (A) Colonies formed by 
ΔSET and wild-type BMCs transduced with CALM-AF10 and MLL-AF9, presented as a 
percentage of wild-type colonies. (B) Colony morphology of ΔSET and wild-type BMCs 
transduced with oncogenes. Scale bars are 100 μm. (C) Wright-Giemsa-stained ΔSET and wild-
type BMCs transduced with oncogenes, at the final round of plating. Scale bars are 20 μm. 
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SK-1 inhibits growth of MA9 but not HM2 mouse bone marrow cells 
 
 The failure of ΔSET BMCs to be transformed by MLL-AF9, together with the function of 
ASH1L in activating HOXA9 and MEIS1, suggested that the KMTase activity of ASH1L might 
be involved in activating an oncogenic transcriptional program in MLL-rearranged leukemia. To 
directly investigate the role of ASH1L KMTase activity, we used the ASH1L KMTase inhibitor 
we developed, SK-1, and the negative control compound SK-nc. SK-1 inhibits ASH1L with an 
in vitro IC50 of 4.6±1.9 μM, while SK-nc binds to ASH1L with more than 100-fold weaker 
affinity. We also tested two other ASH1L inhibitors, 10 (IC50=4.4±0.3 μM) and 11 (IC50=3.8±1.8 
μM). We treated mouse BMCs transformed by MLL-AF9 (MA9) or Hoxa9/Meis1 (HM2) with 
the inhibitors for 12 days. At 4 days of treatment, SK-1 inhibited growth of MA9 cells with GI50 
of 14 μM compared to 50 μM for HM2 cells, suggesting a specific inhibitory effect on MA9 
proliferation (Figure 4.5A and B). 10 also inhibited growth of MA9 cells with nearly twofold 
greater potency than HM2 cells (GI50 of 11 versus 20 μM). In contrast, the negative control 
compound SK-nc had much weaker activity in both cell lines (GI50 of 48 and 70 μM in MA9 and 
HM2 cells, respectively). At 8 days of treatment, SK-1 and 10 showed enhanced activity in MA9 
cells with GI50 of 6 and 10 μM, respectively, while their activity in HM2 cells remained weaker 
with GI50 of 33 and 20 μM, respectively (Figure 4.5C and D). By 12 days of treatment, SK-1 
inhibited growth of MA9 cells with GI50 of 4 μM, more than 7-fold more potent than HM2 cells 
(29 μM) (Figure 4.5E and F). In addition, 10 displayed a greater than 3-fold increased potency 
in MA9 cells (GI50 of 7 μM) compared to HM2 cells (23 μM). At all the time points, inhibitor 11 
showed weak growth inhibition for both MA9 and HM2 cells, suggesting that 11 may be poorly 
cell membrane permeable. The negative control compound SK-nc also maintained weak activity 
in MA9 and HM2 cells at 12 days (GI50 of 34 and 59 μM, respectively). These results indicate 
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that ASH1L inhibitors selectively inhibit growth of MA9 cells over HM2 cells, with SK-1 
exhibiting the most potent and selective effects (Figure 4.5G, H, and I). 
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Figure 4.5. Effect of ASH1L inhibitors on cell viability of MA9 (A, C, and E) and HM2 (B, D, 
and F) cells, after 4 days (A and B), 8 days (C and D), and 12 days (E and F) of inhibitor 
treatment. GI50 values are graphed after 4 days (G), 8 days (H) and 12 days (I). 
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SK-1 induces differentiation of MA9 cells 
 Given the selective growth inhibition of MA9 cells mediated by SK-1, we investigated 
whether SK-1 induces hematopoietic differentiation. We found that MA9 cells treated with 3.1 
μM SK-1 for 12 days had increased cell size, increased number of vacuoles, and decreased 
nuclear-to-cytoplasmic ratio compared to MA9 cells treated with SK-nc, indicating 
differentiation into macrophages (Figure 4.6A). Flow cytometry also showed increased cell size 
(forward scatter) and granularity (side scatter) of MA9 cells treated with SK-1 compared to SK-
nc-treated cells (Figure 4.6B). In addition, in cells treated with 3.1 μM SK-1 we observed a 
slight increase in expression of CD11b (Figure 4.6B), a differentiation marker of myeloid cells, 
and higher concentrations of SK-1 are likely needed to observe a larger effect. MA9 cells treated 
with SK-1 had an increased percentage of cells undergoing apoptosis compared to DMSO- or 
SK-nc-treated cells (Figure 4.6C). Finally, SK-1 but not SK-nc caused a decrease in expression 
of Hoxa genes and Meis1 (Figure 4.6D). Together, these results suggest that SK-1 inhibits 
growth of MA9 cells by blocking ASH1L SET-dependent activation of Hoxa genes and Meis1. 
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Figure 4.6. SK-1 induces differentiation of MA9 cells. (A) Wright-Giemsa-stained MA9 and 
HM2 cells treated for 12 days with 3.1 μM SK-1, 3.1 μM SK-nc or DMSO. Scale bars are 50 
μm. (B) Histograms of forward and side scatter and CD11b expression for MA9 cells treated for 
12 days with 3.1 μM SK-1, 3.1 μM SK-nc, or DMSO, as detected by flow cytometry. (C) 
Apoptosis and necrosis induced by 12 days of SK-1, SK-nc, or DMSO treatment in MA9 cells, 
as detected by Annexin V and propidium iodide staining and flow cytometry. (D) qRT-PCR for 
Hox genes and Meis1 in MA9 and HM2 cells treated for 4 days with SK-1, SK-nc, or DMSO. 
Expression was normalized to β-actin and referenced to DMSO-treated cells. 
 
SK-1 blocks proliferation of MLL-rearranged human leukemic cell lines 
 
 We next tested the effect of SK-1 on proliferation of human leukemia cell lines. For this 
experiment we chose MV4;11 cells, which contain an MLL-AF4 translocation, and MOLM-13 
cells, which harbor an MLL-AF9 translocation. We found that after 4 days of compound 
treatment, SK-1 prevents growth of MV4;11 cells with GI50 of 2 μM, compared to 27 μM for the 
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negative control compound SK-nc (Figure 4.7A). In addition, SK-1 prevents growth of MOLM-
13 cells with GI50 of 9 μM, compared to 38 μM for SK-nc (Figure 4.7B). These results suggest 
that the ASH1L SET domain is required for proliferation of human MLL-rearranged leukemias 
and that targeting ASH1L KMTase activity might represent a promising therapeutic strategy in 
acute leukemia. 
 
Figure 4.7. Growth inhibition by ASH1L inhibitor SK-1 and negative control compound SK-nc 
in human leukemia cell lines MV4;11 (A) and MOLM-13 (B) after 4 days of compound 
treatment. 
 
Discussion 
 
 Numerous studies have provided circumstantial evidence for a role of ASH1L in 
oncogenesis. For example, ASH1L is overexpressed in multiple cancer types and activates Hox 
and Wnt genes, which are dysregulated in many varied tumors [89,195]. Moreover, the ASH1L 
SET domain is a key region of the protein that dimethylates H3K36 and activates Hox gene 
expression during development [93]. Nevertheless, definitive proof of ASH1L’s oncogenic 
activities had previously remained elusive. Here we used genetic and pharmacologic approaches 
to demonstrate that ASH1L activates HOX genes and regulates cell growth in a subset of acute 
leukemia. Our results show that ASH1L is required for proliferation in leukemias driven by MLL 
rearrangements and the CALM-AF10 fusion, but not by Hoxa9/Meis1. Furthermore, using a 
targeted in-frame deletion of the ASH1L AWS-SET domain and a small molecule inhibitor of 
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ASH1L KMTase activity, we provide evidence suggesting that the SET domain in particular is 
important for ASH1L’s oncogenic function. This finding is highly significant given that ASH1L 
is a large epigenetic regulator with multiple chromatin-interacting domains. Although we 
demonstrated a key role for the SET domain in leukemogenesis, the function of the other 
domains remains to be explored. Future studies could test whether combination of ASH1L 
knockdown and an ASH1L SET inhibitor has a more pronounced effect on differentiation of 
leukemia cells than the SET inhibitor alone, which would suggest that other regions of ASH1L 
contribute to leukemogenesis distinctly from the SET domain.  
We found that the ASH1L SET domain is required for leukemic transformation mediated 
by two different fusion proteins, MLL-AF9 and CALM-AF10. AF9 and AF10 are nuclear 
proteins that participate in the same protein interaction network [196], but MLL and CALM 
function in quite different pathways. Wild-type MLL regulates Hox gene expression and is 
essential for hematopoietic development [197,198], while wild-type CALM plays roles in 
clathrin-mediated endocytosis, erythropoiesis, and iron metabolism [199,200]. Nevertheless, a 
common feature of leukemias driven by MLL fusion proteins and the CALM-AF10 fusion is the 
high expression of HOXA genes and MEIS1 [201]. Our finding that ASH1L is important in both 
MLL-AF9- and CALM-AF10-driven leukemia suggests that ASH1L might be an important 
lynchpin in HOX gene activation. In support of this hypothesis, we found that ASH1L activates 
HOX genes in human leukemia THP1 and KG1 cells. THP1 cells harbor an MLL-AF9 
translocation, while KG1 cells lack MLL rearrangements, yet both cell lines have comparably 
high levels of HOXA9 expression relative to the K562 chronic myeloid leukemia cell line (data 
not shown). We have also found that human leukemia cell lines with MLL-AF4 and MLL-AF9 
translocations are sensitive to ASH1L inhibition, suggesting that ASH1L KMTase activity is 
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important in human MLL-rearranged leukemia with varying translocation partner genes. Further 
testing of ASH1L inhibitors in a larger panel of leukemia cell lines will reveal whether the 
ASH1L SET domain is universally important for HOX gene activation and cell proliferation in 
leukemia with high HOX expression.  
 Compared to similar ASH1L inhibitors, SK-1 showed the most potent and selective 
activity on MA9 cells versus HM2 cells (GI50 of 4 μM versus 29 μM at 12 days). Inhibitor 10 
had a similar potency of growth inhibition (GI50 of 7 μM at 12 days) but was not as selective for 
MA9 cells as SK-1, suggesting that 10 may cause some off-target toxicity. Inhibitor 11 showed 
weak growth inhibition for both MA9 and HM2 cells, suggesting that 11 may be poorly cell 
membrane permeable. Cellular testing of additional ASH1L inhibitors and control compounds 
will help further characterize the toxicity and membrane permeability profiles of these 
molecules. Optimization of the pharmacokinetic parameters of ASH1L inhibitors for in vivo 
experiments will also be the subject of future studies. 
In conclusion, we have shown that ASH1L inhibitors developed in our lab have potent 
cellular activity, and at the same time we used the inhibitors to discover a novel role for ASH1L 
in leukemia. ASH1L inhibitors will be valuable tools to investigate the function of the ASH1L 
SET domain in many types of cancer. For example, we have shown that ASH1L regulates 
proliferation of triple negative breast cancer cells, and ASH1L inhibitors can be used to 
determine if the ASH1L SET domain is involved in breast cancer. The ASH1L inhibitors we 
developed have low molecular weight (<400 Da) and are readily accessible synthetically. Future 
work will focus on honing potency and pharmacokinetic properties for in vivo studies with 
animal models of leukemia and breast cancer. 
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Chapter 5. Conclusions and perspectives 
 
Stephen Frye described five principles of a quality chemical probe [202]: 
1) The probe is sufficiently potent and selective in vitro to confidently associate its in 
vitro profile to its cellular or in vivo profile. 
2) Activity in a cell-based or cell-free assay influences a physiologic function of the 
target in a dose-dependent manner. 
3) Has sufficient chemical and physical property data to interpret results as due to its 
intact structure or a well-characterized derivative. 
4) Cellular activity data allow one to confidently address at least one hypothesis about the 
role of the molecular target in a cell’s response to its environment. 
5) The probe is freely available to the academic community with no restrictions on use. 
In this thesis work, we made major strides toward developing the first quality chemical 
probe and small molecule inhibitor of ASH1L. Regarding principle 1, our current most potent 
ASH1L inhibitors bind with 1 μM affinity and show an excellent selectivity profile over related 
histone lysine methyltransferases (KMTases). For principle 2, the inhibitors block ASH1L-
mediated methylation of the physiologically relevant nucleosome substrate, and ChIP assays will 
be conducted to determine the effect of ASH1L inhibitors on histone methylation in cells. In 
regards to principle 3, crystal structures of ASH1L in complex with inhibitors reveal specific 
interactions made by the intact compounds, in agreement with the structure-activity relationship. 
For principle 4, we used the ASH1L inhibitor SK-1 and negative control compound SK-nc to 
discover a new role for ASH1L in leukemia. As for principle 5, we plan to make ASH1L
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inhibitors freely available for researchers around the world to investigate ASH1L’s role in cancer 
and other biological systems. Altogether, we made substantial progress toward fulfilling Frye’s 
principles for a quality chemical probe, and further synthetic modifications in the near future will 
hone potency and cellular activity. Eventually, ASH1L inhibitors could be developed into novel 
therapeutics for human disease.  
The first inhibitors of ASH1L KMTase activity represent a new paradigm in the KMTase 
inhibitor field 
 
Small molecule inhibitors have not been reported for most H3K36-specific KMTases, 
and no inhibitors have been reported for ASH1L or the related NSD proteins, despite strong 
evidence for their oncogenic function (Chapter 1). On the other hand, academic and industrial 
groups have developed multiple inhibitors for KMTases that methylate H3K4, H3K9, H3K27, 
and H3K79 [9,203–205]. The KMTase inhibitors reported to date fall into two categories: SAM-
competitive and histone substrate-competitive. Two of the best characterized SAM-competitive 
inhibitors are EZH2-targeted tazemetostat (EPZ-6438) and DOT1L-targeted pinometostat (EPZ-
5676), both of which are currently in clinical trials. EPZ-6438 was optimized from a high-
throughput screening hit [203], inhibits EZH2 with Ki of 2.5 nM, and has 35-fold selectivity for 
EZH2 over the very closely related EZH1 and >4,500-fold selectivity relative to a panel of 14 
other KMTases [206]. In contrast, development of EPZ-5676 for DOT1L proceeded through 
modification of SAM and was guided by mechanistic and structural understanding of the 
DOT1L-catalyzed reaction [9]. EPZ-5676 inhibits DOT1L with Ki of ≤0.08 nM [207] and has 
>37,000-fold selectivity for DOT1L relative to a panel of other KMTases [207]. The excellent 
selectivity profiles for EPZ-6438 and EPZ-5676 show that while all KMTases utilize SAM, 
potent and selective SAM-competitive inhibitors can be developed for at least a subset of the 
enzymes. On the other hand, histone substrate-competitive inhibitors of SET domain KMTases 
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with superb potency and selectivity have also been reported. As an example, UNC0642 inhibits 
the H3K9 KMTases G9a and GLP with IC50<2.5 nM and is >2,000-fold selective relative to 
other KMTases [205]. Nevertheless, development of SAM- or histone substrate-competitive 
inhibitors may not be the optimal approach for all KMTases, particularly for autoinhibited 
H3K36-specific KMTases that lack a defined histone binding pocket in existing crystal structures 
[134,208]. 
In this thesis work, we developed the first small molecule inhibitors of the H3K36 
KMTase ASH1L. These inhibitors represent a new paradigm in the KMTase inhibitor field. 
Rather than binding to a well-defined SAM or histone binding pocket on the SET domain, the 
ASH1L inhibitors bind to the autoinhibitory loop region and stabilize the autoinhibited 
conformation of the SET domain. Mechanism of action studies are ongoing to determine whether 
the ASH1L inhibitors are competitive with SAM or nucleosome; competition with SAM is 
unlikely given the tertiary ASH1L/SAM/inhibitor complexes observed by crystallographic 
studies, while competition with nucleosome remains a possibility as the inhibitor and 
nucleosome may be unable to simultaneously bind to the SET domain. Regardless, the ASH1L 
inhibitors are better viewed as allosteric inhibitors because rather than bind to a substrate binding 
pocket, they modify the structure and dynamics of the ASH1L autoinhibitory loop region to 
block enzymatic activity. It is intriguing to speculate that ASH1L enzymatic activity in vivo 
might normally be controlled by physiologic allosteric regulation involving the autoinhibitory 
loop. For instance, ASH1L enzymatic activity might be regulated by post-translational 
modification of the autoinhibitory loop, or by binding of the loop to a cofactor molecule. Indeed, 
ostensibly novel small molecule binding sites on proteins discovered in biochemical screens 
sometimes later reveal themselves to be important physiologic regulatory sites that bind to 
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endogenous ligands or cofactors [209,210]. Our studies motivate further research to identify 
allosteric regulatory sites on ASH1L and other SET domains. Moreover, development of 
allosteric inhibitors of SET domain-containing KMTases could be an effective alternative 
strategy compared to the previously reported inhibitors that bind to the SAM or histone substrate 
binding pockets. 
Our studies are additionally highly innovative because we used a fragment-based drug 
discovery approach (FBDD) to develop the first ASH1L inhibitors. Our work represents the first 
successful application of FBDD to KMTases and suggests that FBDD may be a worthwhile 
strategy for developing inhibitors of other KMTases. FBDD may be particularly well-suited to 
identify new allosteric regulatory sites on SET domain-containing proteins. In sum, the 
development of allosteric ASH1L inhibitors using an FBDD strategy represents a highly 
innovative and significant breakthrough in the KMTase inhibitor field. 
Advantages and disadvantages of the FBDD approach 
 In this work we used FBDD to design potent, selective, and cell-active ASH1L inhibitors. 
We started with a fragment screen of 1500 compounds and selected one ligand for medicinal 
chemistry optimization. We did not obtain crystal structures of the ligand/ASH1L complex 
during the initial medicinal chemistry effort, but we still substantially improved binding affinity 
by expanding the pyrrole in the screening hit to an indole. With sufficiently potent compounds 
and an optimized crystallization strategy, we later successfully obtained crystal structures of nine 
compounds in complex with ASH1L, which provided valuable information for additional 
inhibitor design. The FBDD approach resulted in a ligand-efficient, drug-like lead compound 
with cellular activity. 
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 The FBDD approach has several advantages over high-throughput screening (HTS) for 
developing inhibitors of H3K36-specific KMTases. To begin, an HTS campaign that measures 
KMTase activity is susceptible to artifacts, including compounds that alter the substrate or cause 
aggregation of the enzyme. In contrast, FBDD ensured that we found screening hits that form 
specific interactions with the ASH1L SET domain. Second, KMTase inhibitors appear to be rare 
in existing HTS libraries, as three different pharmaceutical companies reported SAM-
competitive inhibitors of the EZH2 KMTase with similar pyridone-containing scaffolds [11]. 
FBDD allowed us to construct a new KMTase inhibitor scaffold starting from a “foothold” 
fragment-like ligand. Finally, FBDD not only identified a novel series of ligands that bind to 
ASH1L but also identified a novel ligand binding site. There were previously no natural or 
synthetic small molecule ligands of the ASH1L autoinhibitory loop region, and static crystal 
structures showed scant space to accommodate a ligand. However, our NMR studies showed 
conformational heterogeneity of the autoinhibitory loop region (Chapter 2), suggesting that a 
ligand-binding pocket might exist transiently in solution, and FBDD confirmed that this site is 
capable of binding small molecules. While many previous efforts were focused on developing 
SAM-competitive inhibitors of KMTases, often by modifying SAM or the natural product 
sinefungin [129,143,144], FBDD led to the discovery of an additional small molecule binding 
region that may be exploited for inhibitor development. 
 On the other hand, FBDD has some disadvantages, mainly associated with time and cost. 
Due to their small size, fragment-like ligands generally have weak binding affinity and must be 
extensively optimized for biological experiments. A major synthetic chemistry effort is therefore 
required. Crystal structures of the ligand bound to the target protein are very important for 
optimization but are not always easily obtained. Even with a co-crystal structure and medicinal 
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chemistry expertise on hand, some fragment binding pockets are too small to allow growth of the 
fragment. In summary, FBDD is a rigorous step-wise approach for designing novel, ligand-
efficient inhibitors, but the time and cost required to obtain cell-active compounds is often larger 
than that required with HTS. 
Improving potency, physicochemical, and pharmacokinetic properties of ASH1L inhibitors 
From the original fragment screening hit 1 that had millimolar binding affinity for 
ASH1L SET, we developed cell-active ASH1L inhibitors with 1 μM potency.  Nevertheless, 
information from the structure-activity relationship and crystal structures demonstrates that many 
opportunities remain for further improving the potency of ASH1L inhibitors. For example, our 
early SAR suggested that binding affinity could be improved by modifying the thioamide 
conjugated phenyl to other heterocyclic rings. In addition, crystal structures suggest that other 
fused ring systems may be preferable over the indole scaffold, due to the potential for a hydrogen 
bond with the backbone carbonyl of K2264. Perhaps the most promising locations for further 
optimization are positions 1 and 6 of the indole. The crystal structure with SK-1 reveals a groove 
formed by the C-terminal residues that could potentially interact with a variety of substituents at 
position 1 (Figure 5.1A). At position 6 of the indole, the SAR demonstrated that hydroxymethyl 
and imidazole with amine linker substituents are preferred over aminomethyl and amino 
substituents (Chapter 3 and Appendix). Interestingly the crystal structure with 11 showed that 
hydroxymethyl at position 6 forms a water-mediated hydrogen bond with the N2261 sidechain, 
whereas the crystal structure with 6 showed that aminomethyl at position 6 points in the opposite 
direction and forms hydrogen bonds with the backbone carbonyl of G2280 and the sidechain of 
N2256 (Figure 5.1B). Therefore, incorporating a substituent at this position capable of 
interacting with both regions of the protein may increase potency. In addition, there is a 
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possibility of expanding the substituent toward residues 2257-2259, which form the C-terminus 
of an α-helix (Figure 5.1B). Finally, we have consistently found that combining substituents at 
the 1 and 6 positions results in an additive effect on binding affinity (Chapter 3 and Appendix). 
As we identify more potent substituents at each position, we will continue to combine them to 
maximize potency. In addition to improving potency, we will simultaneously work to maintain 
adequate physicochemical and pharmacokinetic properties. Fortunately, SK-1 already shares 
characteristics of orally active drugs [211]. SK-1 has molecular weight of 359 Da, four hydrogen 
bond donors, three hydrogen bond acceptors, and clogP of 3.2 (calculated in ChemDraw), 
supporting its further optimization for in vivo studies. 
 
Figure 5.1. Regions for optimization of ASH1L inhibitors. (A) Surface representation of crystal 
structure of ASH1L SET in complex with SK-1, with C-terminal residues highlighted in yellow. 
(B) Overlay of crystal structures of ASH1L in complex with 6 and 11. The different interactions 
made by 6 and 11 are shown. 
 
The role of ASH1L in leukemia 
Our studies revealed a new role for ASH1L in activating Hox genes and regulating cell 
growth in leukemia. Because mouse BMCs transformed by Hoxa9/Meis1 are not sensitive to 
ASH1L inhibitors, our results suggest that ASH1L’s leukemogenic function depends on 
activation of Hoxa9 and Meis1. We further showed that the ASH1L SET domain in particular 
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plays a key role in activating Hox gene expression and driving proliferation of leukemic cells, a 
highly significant finding given that ASH1L is a large epigenetic regulator with multiple 
chromatin-interacting domains. Our finding that ASH1L regulates leukemic cell growth in 
CALM-AF10- and MLL-AF9-driven leukemia suggests that ASH1L may play an important role 
in leukemias with high Hox expression.  
 Future studies will be needed to investigate the details of ASH1L’s role in leukemia. 
Given that ASH1L KMTase activity is important for Hox gene activation, we hypothesize that 
ASH1L activates Hox genes by methylating H3K36 at Hox loci. We failed to detect a change in 
H3K36 dimethylation globally by Western blot upon treatment with ASH1L inhibitors (data not 
shown), likely due to the presence of multiple H3K36-specific KMTases. However, in the near 
future we will more thoroughly investigate ASH1L’s effect on chromatin modifications by 
performing chromatin immunoprecipitation (ChIP) experiments with ASH1L inhibitors.  
Another key topic for future research is the relationship between ASH1L and MLL in 
leukemia, as a partnership between ASH1L and MLL during development is conserved from 
flies to mammals. ASH1 and the MLL homolog TRX are members of the trithorax (TrxG) group 
of epigenetic activators that maintain Hox gene expression during Drosophila development. 
ASH1 and TRX interact genetically, colocalize on salivary gland polytene chromosomes, and 
coimmunoprecipiate each other in embryonic nuclear extracts [212,213]. In mammals, ASH1L 
and MLL cooperate to activate Hox genes and maintain quiescence of long-term hematopoietic 
stem cells [15,198,214,215].  
MLL has a well-characterized role in leukemia, as MLL fusion proteins drive disease in 
10% of human acute leukemia [216], and upregulation of Hox genes is essential for MLL’s 
leukemogenic function [168]. Although ASH1L’s role in leukemia was not previously 
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characterized, our work demonstrates that ASH1L regulates leukemic cell proliferation and 
activates Hox genes, similar to MLL. Further biochemical studies are necessary to determine the 
nature of the relationship between ASH1L and MLL in leukemia. In the near-term, we are 
particularly interested whether combination of ASH1L inhibitors with menin-MLL inhibitors 
[217] or WDR5-MLL inhibitors [204] will result in more potent effects on leukemic cells than 
either treatment alone. We envision three simple models of the ASH1L and MLL relationship 
that would affect the outcome of combination therapy. In the first scenario, ASH1L and MLL 
participate in different pathways that independently contribute to target gene activation (Figure 
5.2, scenario 1). In this case, combination of ASH1L and MLL-targeted inhibitors would be 
expected to have an approximately additive effect on target gene expression. In the second 
scenario, ASH1L and MLL participate in overlapping pathways that together cause a much 
greater activation of target genes than either ASH1L or MLL alone (Figure 5.2, scenario 2). For 
example, MLL-mediated H3K4 methylation could cooperate with ASH1L-mediated H3K36 
methylation to cause a marked upregulation of transcription. In this scenario, inhibiting ASH1L 
or MLL individually would be nearly as effective as inhibiting both proteins. In the third 
scenario, ASH1L and MLL are each individually capable of activating their target genes to near-
maximal levels (Figure 5.2, scenario 3). In this scenario, combining ASH1L and MLL 
inhibitors would have a synergistic effect on downregulating target gene expression. We will 
perform combination therapy experiments in the near future to test these different models. 
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Figure 5.2. Three models of the relationship between ASH1L and MLL in activating target 
genes. In scenario 1, ASH1L and MLL function in separate, independent pathways that each 
contribute to target gene activation. In this case, combining ASH1L and MLL inhibitors would 
be expected to have an approximately additive effect. In scenario 2, ASH1L and MLL cooperate 
to achieve a marked increase in target gene expression, but the individual proteins are poorly 
effective. In this case, combining ASH1L and MLL inhibitors would not have a significantly 
greater effect than either inhibitor alone. In scenario 3, both ASH1L and MLL are individually 
capable of near-maximal target gene activation. In this case, combining ASH1L and MLL 
inhibitors would have a synergistic effect on decreasing target gene expression. 
 
Future directions 
This work demonstrates the successful development of potent and cell-active ASH1L 
inhibitors using an FBDD approach. As outlined above, many exciting opportunities remain for 
further enhancing the potency and optimizing the pharmacokinetic properties of the ASH1L 
inhibitors we developed. Nonetheless, the inhibitors presented here already represent valuable 
tools to investigate many questions surrounding ASH1L’s function in cancer and development. 
ASH1L inhibitors could be used to identify the transcriptional targets of ASH1L on a genome-
wide scale, to elucidate the in vivo methylation targets of ASH1L, and to determine in what cell 
types and developmental stages ASH1L is active. Further biochemical studies will also be 
needed to determine the mechanism whereby ASH1L is recruited to its target loci and what co-
activators cooperate with ASH1L. In addition to cancer, ASH1L has been implicated in the 
pathogenesis of facioscapulohumeral muscular dystrophy and liver fibrosis [86,87], and ASH1L 
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inhibitors could be used to investigate these diseases. We predict that ASH1L inhibitors will 
facilitate many important discoveries surrounding ASH1L’s role in biology. 
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Chapter 6. Materials and Methods 
 
ASH1L constructs 
ASH1L SET (amino acids 2069–2288), ASH1L SET-PHD (amino acids 2069–2636), and 
ASH1L SET-BAH (amino acids 2069–2833) were cloned from the full-length human ASH1L 
cDNA. ASH1L N-SET (amino acids 2003–2303) was codon-optimized for expression in 
Escherichia coli, and the DNA was purchased from Life Technologies. Point mutations were 
made in SET and SET-BAH constructs by polymerase chain reaction (PCR) and confirmed by 
DNA sequencing. 
Protein purification 
 
ASH1L SET and N-SET proteins were expressed as MOCR fusion proteins in E. 
coli BL21(DE3) T1R cells at 22 °C. Transformed cells were lysed in buffer A containing 50 mM 
Tris (pH 7.5), 500 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), and 20 mM 
imidazole. Cell debris was pelleted by centrifugation, and the supernatant was loaded on a 
column packed with nickel-nitrilotriacetic acid beads. The column was washed with buffer A and 
protein eluted with a 100 mL linear gradient up to buffer A containing 500 mM imidazole. The 
MOCR tag was cleaved with tobacco etch virus (TEV) protease during overnight dialysis against 
50 mM Tris (pH 7.5), 100 mM NaCl, and 1 mM TCEP. Cleaved ASH1L was isolated from 
MOCR by repeating the nickel column purification and collecting ASH1L in the flow-through 
and low-imidazole fractions. ASH1L was further purified by gel filtration chromatography using 
a Superdex-75 column running in buffer B containing 50 mM Tris (pH 7.5), 100 mM NaCl, and 
1 mM TCEP. ASH1L SET-PHD and SET-BAH proteins were purified similarly, with the
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following differences. Expression was performed at 18 °C; cleavage with TEV and the second 
nickel column were omitted to maintain protein stability, and gel filtration was performed on a 
Superdex-200 column. 
NMR studies 
15
N-
13C ASH1L SET was prepared at 300 μM concentration in buffer containing 50 mM 
HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP, and 300 μM S-adenosyl methionine (SAM). HSQC 
Spectra were acquired at 25 and 30°C with a Bruker Avance III spectrometer equipped with 
cryoprobe, running Topspin version 2.1. Backbone assignment was performed using triple 
resonance experiments: HNCA, HN(CO)CA, HNCACB, and CBCA(CO)NH. For analysis of 
ASH1L mutants, wild-type and mutant ASH1L SET proteins were prepared at 100 μM 
concentration in 50 mM Tris pH 7.5, 50 mM NaCl, 1 mM TCEP, 200 μM SAM, 5% DMSO, and 
5% D2O. 
1
H-
15
N TROSY spectra were acquired at 30°C. All NMR processing and spectral 
visualization were performed using NMRPipe [218] and Sparky [219]. 
Chemical shift perturbations (Δ) in 15N-1H TROSY spectra caused by mutations 
compared to wild-type were calculated as the square root of the sum of the squares of the 
differences in the 
1
H and 
15
N chemical shifts [220], 
Δ = [(δH x 600)
2
 + (δN x 60.8)
2
]
1/2
    (1) 
where δH and δN  are the chemical shift differences in ppm between mutant and wild-type for 
1
H 
and 
15
N, respectively. Global structural perturbations caused by mutations were determined by 
calculating the sum of Δ for all amides (Δsum). 
NMR fragment screening 
 
15
N-labeled ASH1L SET was prepared at a 100 μM concentration in 50 mM Tris pH 7.5, 
50 mM NaCl, 1 mM TCEP, and 200 μM SAM. Approximately 1500 fragment-like ligands from 
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an internal collection in Dr. Cierpicki’s lab were screened in 10 or 20-compound mixtures at 
either 250 or 500 μM concentration in a final DMSO concentration of 5%. TROSY spectra were 
recorded at 30°C. Compound mixtures causing chemical shift perturbations compared to DMSO 
were deconvoluted to identify ASH1L ligands. 
NMR-based 3PA Measurements 
 
The 3PA measurement for measuring relative binding affinity of compounds was 
calculated by taking the average of the chemical shift perturbations in hertz at three 
15
N-
1
H 
TROSY peaks (G2163, K2228, and I2278) in the presence of 500 μM compound. Chemical shift 
perturbations caused by compound binding were calculated as in equation 1 above. 
KMTase assay 
 
Chicken mono/dinucleosomes (HMT-35-179), chicken oligo nucleosomes (HMT-35-
177), and HeLa nucleosomes (HMT-35-123) were purchased from Reaction Biology. 
Recombinant nucleosomes were purified in house as described previously [221]. For testing 
different ASH1L constructs and nucleosome substrates, ASH1L (0.25 μM) was incubated with 
0.7 μM SAM and 0.2 or 0.4 μM nucleosome in HMTase buffer containing 50 mM Tris (pH 8.5), 
25 mM NaCl, 2 mM MgCl2, and 1 mM DTT in a total volume of 25 μL for 1 h at 30 °C. For 
assays with ASH1L mutants, ASH1L SET-BAH WT and mutant proteins (0.25 μM) were 
incubated with 20 μM SAM (5% radiolabeled [3H]SAM) and 1.7 μM chicken 
mono/dinucleosomes in HMTase buffer in a total volume of 10 μL for 1 h at 30 °C. For testing 
compounds, ASH1L SET-BAH (0.25 μM) was incubated with 0.7 μM SAM, 0.2 μM chicken 
mono/dinucleosomes, and the compound in a concentration range from 500 to 0.2 μM in 
HMTase buffer in a total volume of 15 μl for 1 hr at 30 °C. For testing specificity of ASH1L 
inhibitors, assay conditions were identical except NSD1, NSD2, NSD3, SETD2, and EHMT2 
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(0.2 μM) were substituted for ASH1L SET-BAH. The reactions were stopped by spotting 5 μL 
of the reaction mixture on P81 cellulose squares (Reaction Biology). The P81 squares were dried 
for 45 min and washed five times with 50 mM sodium bicarbonate (pH 9.0), 10 min per wash. 
The P81 squares were then dried for 1 h, added to 10 mL of Ultima Gold scintillation cocktail 
(PerkinElmer), and analyzed using a Beckman scintillation counter.  
Isothermal titration calorimetry 
 
 ASH1L SET was extensively dialyzed at 4°C against ITC buffer (50 mM sodium 
phosphate pH 7.5, 50 mM NaCl, 1 mM TCEP). Compounds were dissolved in DMSO and 
diluted with ITC buffer to final concentrations of 0.1-1 mM in 5% DMSO. The protein solution 
was adjusted to 5% DMSO final concentration. Both protein and compound solutions were 
adjusted to 50-100 μM SAM, to maintain ASH1L stability. The titrations were performed using a 
VP-ITC titration calorimetric system (MicroCal) at 25°C. The calorimetric cell, containing 
ASH1L (concentration ranging from 10-50 μM) was titrated with the compounds (concentration 
ranging from 0.1-1 mM) injected in 10 μl volumes. Data was analyzed using Origin 7.0 
(OriginLab) to obtain thermodynamic parameters. 
Crystallization and structure determination 
 
ASH1L wild-type and mutant SET domain proteins in 50 mM Tris (pH 7.5), 100 mM 
NaCl, and 1 mM TCEP were concentrated to 10 mg/mL. Crystals of ASH1L SET domain wild-
type as well as S2259M, K2264L, and H2193F mutants were obtained using the sitting drop 
method in 20 mM Tris (pH 7.5) and 25% PEG3350 at 4 °C. Q2265A crystals were obtained 
using the sitting drop method in 0.1 M Tris (pH 8.5), 0.2 M MgCl2, and 30% PEG4000 at 17 °C. 
For cryoprotection, crystals of WT, S2259M, K2264L, and H2193F were soaked in a 
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crystallization solution containing 20% glycerol, while Q2265A crystals were soaked in a 
crystallization solution containing 25% PEG400.  
For crystallization of ASH1L Q2265A with compounds, 7 mg/ml protein was mixed with 
equimolar compound in a final DMSO concentration of 5%. Crystal seeds were produced by 
vortexing ASH1L Q2265A crystals with a Seed Bead (Hampton). Crystals were obtained using 
the sitting drop method by adding the ASH1L Q2265A/compound complex solution 1:1 with 
crystal seeds in 0.1 M Tris (pH 8.5), 0.2 M MgCl2, and 30% PEG4000 and incubating at 17 °C. 
All data were collected under cryogenic conditions at Life Sciences-Collaborative Access 
Team beamlines 21ID-D, -F, and -G at the Advanced Photon Source at Argonne National 
Laboratory (Argonne, IL). Data were processed with HKL2000 [222]. Structures were 
determined by molecular replacement using MOLREP [223] with the wild-type ASH1L structure 
[Protein Data Bank (PDB) entry 3OPE] as a search model in molecular replacement. Models 
were built and refined using REFMAC5 [224], Coot [225], and the CCP4 package [226]. 
Validation of structures was performed using MolProbity [227]. 
Average crystallographic B factors per residue were calculated as the average of the B-
factors for all the atoms of each residue. Then the residue B factors were normalized using the 
‘z-score normalization’ [228],  
Bx-zscore(i) = [Bx(i)-<B>(i)]/s(i),     (2) 
where Bx-zscore(i) is the normalized z-score for residue x in structure i, Bx(i) is the B-factor for 
residue x, <B>(i) is the average residue B-factor for structure i, and s(i) is the corresponding 
standard deviation.  
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Cell culture 
 
 MDA-MB-468 cells were cultured in DMEM supplemented with 10% FBS, MEM non-
essential amino acids (Thermo Fisher), and 1% penicillin/streptomycin. MCF-7 cells were 
cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. MLL-AF9 
(MA9) transformed murine bone marrow cells (BMCs) were prepared as described previously 
[229]. MA9 BMCs were cultured in Iscove's modified Dulbecco's medium (IMDM) 
supplemented with 15% FBS (Stem Cell Technologies), 10 ng/ml IL-3, and 1% P/S. MV4;11 
and MOLM-13 cells were cultured in RPMI-1640 medium with 10% FBS and 1% 
penicillin/streptomycin. THP-1 cells were cultured in RPMI-1640 medium with 10% FBS and 
1% penicillin/streptomycin. KG1 cells were cultured in IMDM with 20% FBS and 1% 
penicillin/streptomycin. 
Cell viability assays 
 
MA9 and HM2 cells were plated at 1 x 10
5
 cells/ml in 24-well plates, treated with 0.25% 
DMSO or compounds and cultured at 37°C for 12 days. Every four days, the volume 
corresponding to 1 x 10
5 
cells of DMSO-treated cells was spun down and resuspended in fresh 
media with fresh compound. At day 0 and each four day interval, 100 μl aliquots of the cell 
suspension were transferred to 96-well plates in quadruplicates. The quadruplicate samples were 
incubated for 4 days at 37°C, and then an MTT cell proliferation assay kit (Roche) was used to 
measure viable cells. Absorbance was read at 570 nm using a PHERAstar (BMG) microplate 
reader. 
Quantitative RT-PCR 
 
Total RNA was extracted from cells using the RNeasy mini kit (QIAGEN), and then 100-
2000 ng of total RNA was reverse transcribed using the High Capacity cDNA Reverse 
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Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. Real-time PCR 
was performed using a CFX96 Real-Time PCR Detection System (Biorad). TaqMan Gene 
Expression Master Mix and TaqMan Gene Expression Assays for human HPRT1 (Hs02800695), 
human ASH1L (Hs00218516), human HOXA5 (Hs00430330), human HOXA9 (Hs00365956), 
human HOXA10 (Hs00172012), human MEIS1 (Hs00180020), mouse Gapdh (Mm99999915), 
mouse Ash1l (Mm00467322), mouse Hoxa7 (Mm00657963), mouse Hoxa9 (Mm00439364), 
mouse Hoxa10 (Mm00433966), mouse Meis1 (Mm00487664), and mouse B-actin 
(Mm00607939) were purchased from Thermo Fisher. Relative quantification of each gene 
transcript was carried out using the ΔΔCt method as described in the Biorad Real-Time PCR 
Applications Guide. 
Cytospin/Wrigtht-Giemsa staining 
 
1 x 10
5 
MA9 mouse BMCs treated with compounds were harvested and placed in a 
Shandon EZ Single Cytofunnel (Thermo Fisher). Samples were centrifuged at 600 rpm for 5 
min. The slides were air dried before staining with a Hema-3 kit (Thermo Fisher). 
Expression of CD11b and apoptosis 
 
 For CD11b expression analysis, 1.2 x 10
5
 MA9 mouse BMCs treated with compounds 
were harvested and washed with FACS buffer (PBS, 1% FBS, 0.1% NaN3). Cells were 
resuspended in100 μl FACS buffer and incubated with 1 μl Pacific Blue rat anti-mouse CD11b 
antibody (BioLegend cat# 101224) at 4°C for 30 min. Cells were then washed and analyzed by 
flow cytometry. For analysis of apoptosis and necrosis, cells were washed with Annexin V 
binding buffer and incubated with 4 μl Annexin V-FITC (BD Biosciences) and 6 μl propidium 
iodide (1mg/ml, Sigma-Aldrich) at 25°C for 10 min before being analyzed by flow cytometry.
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Appendix. Selected ASH1L inhibitors synthesized to date 
Table A.1. Selected ASH1L inhibitors synthesized to date. 
Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
12B5 1 202.3 7.76 N/A 
    
 
  
BD595 
 
203.3 n.b. N/A 
    
 
  
BD597 1a 213.3 25.38 N/A 
    
 
 
 
BD605 
 
243.3 16.48 N/A 
    
 
  
BD606 
 
243.3 3.63 N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BD608 
 
229.3 16.30 N/A 
    
 
  
BD609 1b 229.3 29.76 N/A 
    
 
  
BD610 
 
292.4 29.26 N/A 
    
 
  
BD632 1c 243.3 48.71 N/A 
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BD633 1d 243.3 36.31 N/A 
    
 
 
 
BD634 
 
319.4 n.b. N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BD635 
 
229.3 18.14 N/A 
    
 
  
BD638 1e 230.29 2.07 N/A 
    
 
  
BD639 1g 230.29 40.45 N/A 
    
 
  
BD640 1f 230.29 n.b. N/A 
    
 
  
BD660 1i 243.32 21.08 N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BD661 1h 243.32 16.35 N/A 
    
 
  
BD673 
 
253.32 7.70 N/A 
    
 
  
BD685 
 
229.3 5.57 N/A 
    
 
  
BD697 
 
244.31 n.b. N/A 
    
 
  
BD698 
 
258.34 n.b. N/A 
    
 
  
BD699 
 
247.29 7.05 N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BD700 
 
247.29 23.28 N/A 
    
 
  
BD701 
 
247.29 19.75 N/A 
    
 
  
BD702 
 
247.29 n.b. N/A 
    
 
  
BD710 
 
253.32 50.60 N/A 
    
 
  
BD720 2 252.34 N/A 30% 76 
   
 
  
BD725 
 
247.29 43.93 N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
BD726 
 
247.29 31.15 N/A 
    
 
  
BD727 
 
257.35 4.73 N/A 
    
 
  
BD748 
 
282.36 6.00 N/A 
    
 
 
 
BD749 
 
281.38 6.12 N/A 
    
 
  
BD756 
 
268.33 44.94 N/A 
    
 
  
BD757 
 
257.35 38.53 N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
BD759 
 
214.29 3.67 N/A 
    
 
 
 
BD770 
 
282.36 9.15 N/A 
    
 
 
 
BD797 
 
242.3 23.23 N/A 
    
 
  
BD818 
 
268.33 7.32 N/A 
    
 
  
BD819 
 
268.33 N/A 20% 
    
 
  
BD840 
 
267.35 n.b. N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
BD842 
 
259.32 N/A 10% 
    
 
  
BD845 
 
214.29 11.47 N/A 
    
 
  
BD848 
 
281.38 8.23 N/A 
    
 
  
BD944 3 252.34 N/A 50% 100 
   
 
  
BD954 
 
282.36 N/A 90% 22 
  
12.1 
 
  
BD955 
 
266.36 N/A 80% 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
BDY-19 4 296.39 N/A 90% 22 
   
 
  
BDY-20 
 
310.37 N/A 50% 
    
 
  
BD990 
 
295.4 N/A 50% 26 
   
 
  
BDY-29 
 
295.36 p.s. N/A 
    
 
  
BDY-33 
 
311.42 N/A 50% 86 
   
 
 
 
BDY-64 
 
267.35 w.b. N/A 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BDY-66 
SK-
nc 
268.33 w.b. N/A 
    
 
 
 
BDY-67 
 
268.33 w.b. N/A 
    
 
 
 
BDY-73 5 281.38 N/A 70% 36 
   
 
 
 
BDY-78 
 
266.36 N/A 20% 
    
 
  
DA-24 
 
267.35 w.b. N/A 
    
 
  
DA-51 
 
282.36 N/A 50% 136 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
DA-53 
 
281.38 N/A 50% 
    
 
  
BD1104 6 325.43 N/A 90% 13 
  
4.6 
 
  
BD1132 
 
253.32 w.b. N/A 
    
 
 
 
BD1143 
 
309.39 N/A 80% 42 
   
 
  
BD1151 
 
295.4 N/A 80% 36 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
BD1155 
 
323.41 N/A 80% 29 
   
 
  
DJM10 
 
267.35 N/A 100% 45 
   
 
 
 
DJM7A 
 
310.42 N/A 50% 43 
   
 
  
DJM7B 
 
368.5 N/A 50% 
    
 
 
 
DJM23 7 311.4 N/A 100% 22.7 
  
4.0 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
DJM29 
 
326.48 p.s. N/A 
    
 
 
 
DJM30 
 
338.43 N/A 60% 
    
 
  
DJM26 
 
268.34 w.b. N/A 
    
 
  
DJM34 
 
341.49 N/A 100% 15.3 
   
 
  
DJM44 
 
281.38 N/A 80% 
    
126 
 
Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
DJM55 8 377.43 N/A 100% 7.5 
  
3.4 
 
  
DJM58 
 
347.44 N/A 100% 33 
   
 
  
DJM69 9 345.41 N/A 100% 3.5 3.7 3.6±0.1 2.0 
 
 
 
DJM78 
 
393.43 N/A 90% 28 
  
3.7 
 
  
DJM-94 
 
341.43 N/A 100% 11 
  
14 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
DJM-97 
 
341.39 N/A 60% 
    
 
 
 
JJ-158 
 
460.56 N/A 40% 
    
 
  
JJ-159 
 
377.43 N/A 50% 
    
 
  
JJ-164 
 
502.6 N/A 80% 
    
 
  
JJ-165 
 
461.55 N/A 30% 
    
128 
 
Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
 
 
JJ-161 
 
481.58 N/A 100% 4.1 
   
 
  
JJ-179 10 471.55 N/A 100% 4.1 4.7 4.4±0.3 2.1 
 
  
JJ-185 
 
482.57 N/A 100% 6.5 
   
 
  
SKA-
125  
355.46 N/A 50% 34 
   
 
 
 
JJ-186 11 392.44 N/A 100% 2.0 5.6 3.8±1.8 2.1 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
JJ-189 
 
349.5 N/A 80% 34 
   
 
  
SKA-
137 
SK-1 359.44 N/A 100% 2.7 6.4 4.6±1.9 1.7 
 
  
JJ-195 
 
335.47 N/A 100% 7.8 
   
 
  
JJ-197 
 
473.52 N/A 100% 5.4 
  
2.5 
 
  
SKM-
144  
453.56 N/A 100% 5.6 6.7 6.2±0.6 1.4 
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Structure Lab ID 
Text 
ID MW 
NMR 
fast 
ex.: 
3PA 
(Hz)
a 
NMR 
slow 
ex.: % 
sat. at 
100 μM 
cmpd 
Enz. 
Assay 
IC50 
Trial 1 
(μM) 
Enz. 
Assay 
IC50 
Trial 2 
(μM) 
Enz. 
Assay 
IC50 
Mean±St
dev. 
(μM) 
Kd 
by 
ITC 
(μM) 
 
  
SKA-
153  
433.52 N/A 100% 5.3 
   
 
  
SKA-
174 
12 374.45 N/A 100% 
   
1.1 
 
  
JJ-228 13 360.42 N/A 100% 
   
0.9 
a
n.b. denotes no binding, w.b. denotes weak binding, and p.s. denotes poorly soluble.
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